Overview	The Test Case document is comprised of three tabs. The first tab is this tab (Overview) and is merely a high-level tab to orient the user in regards to the other tabs. It **should not** be used to infer, interpret, or assume any logic or values. The second tab is the test case layout tab which describes the layout of the test cases on the third and final tab. The third tab are the test cases with one test case per row. All test cases in this file focus on patients who have an underlying condition which would result in an immunity, contraindication, or indication.

Resources	Recommended Immunization Schedule for Persons Aged 0 through 18 years - http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
	Recommended Immunization Schedule for Adults Age 19 Years and Older - Recommended Immunization Schedule for Adults Age 19 Years and Older - http://www.cdc.gov/vaccines/schedules/hcp/adult.html
	General Recs – MMWR/ January 28, 2011 / Vol. 60 / No. 2 - http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm
	IIS Standard Code Sets - http://www.cdc.gov/vaccines/programs/iis/code-sets.html
	DTaP - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dtap.html
	Hep A - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html
	Hep B - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html
	Hib - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html
	HPV - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html
	Influenza - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html
	Japanese Encephalitis - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/je.html
	Measles Mumps and Rubella - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html
	Meningococcal - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html
	Pneumococcal - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html
	Polio - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.html
	Rotavirus - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/rotavirus.html
	Tdap/Td - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html
	Typhoid - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/typhoid.html
	Varicella - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html
	Yellow Fever - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/yf.html
	Zoster - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html

Column	Field Name	Description
A	CDC_Test_ID	Simple numerical identifier for the test case.
B	Test_Case_Name	Human-readable test name to briefly describe the test case.
C	DOB	Date of birth of the patient. DOB format: MM/DD/YYYY (e.g., 01/01/2000).
D	Gender	Gender of the patient. Either M or F (Male or Female)
E	Observation_Code_1	Observation Code is the CDSi defined coded value based on ACIP language. See Supporting Data file "ScheduleSupportingData - Coded Observations.xlsx" for the full list.
F	Observation_Text_1	Observation text is the human readable text associated with the code in the previous column.
G	Observation_Date_1	Observation Date is the date associated with the observation.
H – M	Observations 2 and 3	Observations 2 and 3. This is a repitition of fields E - G.
N	Series_Status	Series Status is the measure of the patients status in relationship to presumed immunity.
O	Date_Administered_1	Date vaccine dose was administered. Date format: MM/DD/YYYY (e.g., 01/01/2000).
P	Vaccine_Name_1	Human readable trade name or the unspecified formulation of the vaccine.
Q	CVX_1	Coded value to define the type of vaccine. Together with MVX the trade name can be inferred.
R	MVX_1	Coded value to define the manufacturer of the vaccine. Together with CVX the trade name can be inferred. If an unspecified formulation is used, no MVX is specified.
S	Evaluation_Status_1	Expected evaluation status (Valid, Not Valid, Extraneous) of the vaccine dose administered based on the ACIP recommendations. In the case of a combination shot, the Expected Evaluation Status is related to the Vaccine Group targeted by the particular test case. The other components of the combination vaccine are tested in their respective Vaccine Group test cases.
T	Series_Type_1	Provides the Series Type (Standard or Risk) where the Evaluation Status was determined.
U	Evaluation_Reason_1	Provides further information as to why the dose administered was not valid. In the case of a combination shot, the reason is related to the Vaccine Group targeted by the particular test case. The other components of the combination vaccine are tested in their specific Vaccine Group test cases.
V - BK	Vaccine Doses Administered 2 through 7. This is a repetition of fields O-U	Vaccine Doses Administered 2 through 7. This is a repetition of fields O-U
BL	Forecast_#	Target Dose being forecasted. If Target Doses 1 and 2 have been satisfied, the Target Dose Number being forecasted would be Target Dose Number 3. If the patient no longer requires a dose (complete, immune, contraindication), the forecast_# is set to “-“.
BM	Earliest_Date	Earliest point in time which the next vaccine dose could be administered and still be considered valid. This does not include the 4-day grace period. Date format: MM/DD/YYYY (e.g., 01/01/2000).
BN	Recommended_Date	Date at which the next vaccine dose administered should be given. Date format: MM/DD/YYYY (e.g., 01/01/2000).
BO	Past_Due_Date	Date at which the patient is considered overdue for their immunization. Date format: MM/DD/YYYY (e.g., 01/01/2000).
BP	Administrative_Guidance	Administrative Guidance is used to provide additional - usual non-computable or overly complex ACIP language - information to the clinician to aid in decision making.
BQ	Vaccine_Group	The Vaccine Group being tested with the test case.
BR	Assessment Date	Assessment Date is the date which should be used during evaluation and forecasting rather than the current date. This is used to help with test cases which would become invalid over time.
BS	Evaluation_Test_Type	Evaluation Test Type is used to categorize the test case. This will allow testers to focus in on categories of tests as needed.
BT	Date_Added	This is the date the test case was created. The format is MM/DD/YYYY. (e.g.: 01/01/2000)
BU	Date Updated	This is the date the test case was changed. The format is MM/DD/YYYY. (e.g.: 01/01/2000)
BV	Forecast_Test_Type	Forecast Test Type is used to categorize the test case. This will allow testers to focus on categories of tests as needed.
BW	Reason_For_Change	As test cases are changed, this field is used to document the reason the test case was changed.
BX	Changed_In_Version	This field documents the version number the test case was last changed.

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2015-UC-0012	Varicella: Zoster dose administered at 50 years - 1 day	05/29/1965	F	055	Health care personnel								Not Complete	05/28/2015	Zostavax	121		Valid	standard																		
2016-UC-0002	Anaphylaxis to previous dose	10/10/2010	F	080	Adverse reaction to vaccine component								Contraindicated	12/10/2010	DTaP Unspecified	107		Valid	standard																		
2016-UC-0003	Encephalopathy within 7 days of Pediarix.	02/02/2011	F	079	Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine								Not Complete	04/02/2011	PEDIARIX	110	SKB	Valid	standard																		
2016-UC-0004	Anaphylaxis to previous dose of Pediarix	10/10/2010	F	080	Adverse reaction to vaccine component								Contraindicated	12/15/2010	PEDIARIX	110	SKB	Valid	standard																		
2016-UC-0005	Anaphylaxis to previous dose of Pentacel	06/06/2010	F	080	Adverse reaction to vaccine component								Contraindicated	08/02/2010	PENTACEL	120	PMC	Valid	standard																		
2016-UC-0006	Anaphylaxis following previous dose of Influenza	07/04/2013	F	085	Severe allergic reaction after previous dose of Influenza								Contraindicated	10/08/2014	Influenza Unspecified	88		Valid	standard																		
2016-UC-0007	Anaphylaxis to previous dose of Hep A. No forecast.	03/03/2003	F	096	Severe allergic reaction after previous dose of Hepatitis A								Contraindicated	03/04/2009	Hep A Unspecified	85		Valid	standard																		
2016-UC-0008	Anaphylaxis to previous dose of Hep B. No further forecast.	09/09/2006	F	097	Severe allergic reaction after previous dose of Hepatitis B								Contraindicated	11/11/2006	RECOMBIVAX-PED5	08	MSD	Valid	standard																		
2016-UC-0009	Anaphylaxis to previous dose of Pentacel (Hib)	06/06/2010	F	080	Adverse reaction to vaccine component								Contraindicated	08/02/2010	PENTACEL	120	PMC	Valid	standard																		
2016-UC-0010	Anaphylaxis to previous dose of HPV Vaccine	05/19/2000	F	090	Severe allergic reaction after previous dose of HPV								Contraindicated	06/19/2011	HPV Unspecified	137		Valid	standard																		
2016-UC-0011	Anaphylaxis to previous dose of MCV	02/26/2000	F	095	Severe allergic reaction after previous dose of Meningococcal								Contraindicated	03/15/2011	Meningococcal MCV4 Unspecified	147		Valid	standard																		
2016-UC-0012	Anaphylactic reaction to dose 1 of MMR. No forecast for additional dose.	08/13/2010	F	091	Severe allergic reaction after previous dose of Measles								Contraindicated	09/02/2011	M-M-R II	03	MSD	Valid	standard																		
2016-UC-0013	Diagnosis of severe immunodeficiency. No forecast for MMR.	09/10/2011	F	154	HIV/AIDS - severely immunocompromised								Contraindicated																								
2016-UC-0014	Anaphylaxis to previous dose of PCV7. No forecast.	07/11/2007	F	094	Severe allergic reaction after previous dose of Pneumococcal								Contraindicated	09/11/2007	PREVNAR 7	100	WAL	Valid	standard																		
2016-UC-0015	Anaphylaxis to previous dose. No forecast.	07/24/2011	F	081	Severe allergic reaction after previous dose of Polio		108	Severe allergic reaction to streptomycin					Contraindicated	09/24/2011	IPOL	10	PMC	Valid	standard																		
2016-UC-0016	Severe combined immunodeficiency (SCID)=no rotavirus vaccine	02/01/2012	F	013	Severe Combined Immunodeficiency [SCID]								Contraindicated																								
2016-UC-0017	Anaphylaxis following previous dose	02/01/2012	F	083	Severe allergic reaction after previous dose of Rotavirus								Contraindicated	04/01/2012	ROTARIX	119	SKB	Valid	standard																		
2016-UC-0018	Anaphylaxis following previous dose	02/01/2012	F	083	Severe allergic reaction after previous dose of Rotavirus								Contraindicated	04/01/2012	ROTATEQ	116	MSD	Valid	standard		05/01/2012	ROTARIX	119	SKB	Valid	standard											
2016-UC-0019	History of VZ Titer of immunity to VZ=series complete or	05/01/2004	F	024	Healthcare provider verified history of or diagnosis of Varicella	04/01/2005							Immune																								
2016-UC-0020	exempt	06/01/2005	F	024	Varicella								Immune																								
2016-UC-0021	Anaphylactic reaction to dose 1 of VZ	12/12/2010	F	089	Severe allergic reaction after previous dose of Varicella								Contraindicated	03/15/2012	VARIVAX	21	MSD	Valid	standard																		
2016-UC-0022	Diagnosis of severe immunodeficiency. No second dose.	12/12/2009	F	154	HIV/AIDS - severely immunocompromised								Contraindicated	12/20/2010	VARIVAX	21	MSD	Valid	standard																		
2016-UC-0023	Diagnosis of severe immunodeficiency before administration of any VZ. No VZ to be given.	11/18/2010	F	154	HIV/AIDS - severely immunocompromised								Contraindicated																								
2016-UC-0024	Varicella: Patient has laboratory evidence of immunity for Varicella	06/16/1990	F	023	Laboratory Evidence of Immunity or confirmation of Varicella disease								Immune																								
2016-UC-0025	Varicella: Patient has a Varicella verifiable diagnosis by a healthcare provider.	06/16/1983	F	024	Healthcare provider verified history of or diagnosis of Varicella								Immune																								

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0026	Varicella: Patient has a Herpes Zoster verifiable diagnosis by a healthcare provider.	06/19/1972	F	024	Healthcare provider verified history of or diagnosis of Varicella								Immune																							
2016-UC-0027	varicella: Patient is a healthcare worker with a one-dose history of Varicella vaccine.	03/28/1968	F	055	Health care personnel								Not Complete	05/28/2015	VARIVAX	21	MSD	**Valid**	**standard**																	
2016-UC-0028	Varicella: Patient is a healthcare worker with evidence of immunity for Varicella.	05/20/1968	M	055	Health care personnel								Complete	07/03/2012	VARIVAX	21	MSD	Valid	standard		07/31/2012	Varivax	21		Valid	standard										
2016-UC-0029	varicella: Patient is pregnant, and has not been found to have evidence of immunity for Varicella.	06/19/1977	F	007	Pregnant								Contraindicated																							
2016-UC-0031	Zoster Live Vaccine: Anaphylactic reaction to Zoster vaccine components (Gelatin or neomycin)	06/16/1955	F	107	Severe allergic reaction to neomycin								Not Complete																							
2016-UC-0032	MMR: Patient is a healthcare worker, born before 1957, has received one dose of the MMR vaccine.	08/12/1955	F	055	Health care personnel								Not Complete	04/30/2015	M-M-R II	03	MSD	**Valid**	**standard**																	
2016-UC-0033	Patient is 31 years of age, vaccine naive, and seeking protection from Hep A	04/01/1985	M	001	Patient seeks protection								Not Complete																							
2016-UC-0034	Patient is an adult seeking protection from Hepatitis A, and has received the first dose of the risk 2 dose series.	05/27/1978	M	001	Patient seeks protection								Not Complete	07/01/2016	Hep A, adult	52	MSD	Valid	risk																	
2016-UC-0035	Patient is an adult seeking protection from Hepatitis A, and has received the second dose of the Hep A risk 2-dose series.	03/17/1991	F	001	Patient seeks protection								Complete	05/01/2016	Hep A, adult	52	MSD	Valid	risk		11/01/2016	Hep A, adult	52	MSD	Valid	risk										
2016-UC-0036	Patient is 55 years of age, has chronic liver disease, and has not received Hepatitis A vaccine.	04/12/1961	F	015	Chronic liver disease								Not Complete																							
2016-UC-0037	Patient has Chronic liver disease and has received the first dose of the Hep A risk Twinrix 3 dose series .	04/12/1961	F	015	Chronic liver disease								Not Complete	08/01/2016	HepA-HepB	104	SKB	Valid	risk																	
2016-UC-0038	Patient has Chronic liver disease and has received the second dose of the Hep A risk Twinrix 3 dose series .	02/15/1967	M	015	Chronic liver disease								Not Complete	04/01/2016	HepA-HepB	104	SKB	Valid	risk		04/29/2016	HepA-HepB	104	SKB	Valid	risk										
2016-UC-0039	Patient has Chronic liver disease and has received all three doses of the Hep A risk Twinrix 3 dose series .	07/25/1966	M	015	Chronic liver disease								Complete	08/05/2016	Hep A	104	SKB	Valid	risk		09/02/2016	HepA-HepB	104	SKB	Valid	risk		02/04/2017	HepA-HepB	104	SKB	Valid	risk			

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0040	Patient is 26 years of age, a Public safety worker exposed to blood or infectious body fluids and has not received the Hepatitis B vaccine. Patient is a Public Safety worker and seeks protection and has received the second dose of the Twinrix 4 dose series.	01/12/1990	M	057	Public safety worker exposed to blood or infection body fluids								Not Complete																							
2016-UC-0042		03/29/1983	M	001	Patient seeks protection								Not Complete	05/17/2016	Hep B	104	SKB	Valid	risk		05/24/2016	Hep B	104	SKB	Valid	risk										
2016-UC-0043	Patient is a Public Safety worker and seeks protection and has received the third dose of the Twinrix 4 dose series.	03/29/1983	M	001	Patient seeks protection								Not Complete	05/17/2016	Hep B	104	SKB	Valid	risk		05/24/2016	Hep B	104	SKB	Valid	risk		06/07/2016	Hep B	104	SKB	Valid	risk				
2016-UC-0044	Patient is a Public safety worker exposed to blood or infectious body fluids and has received all four doses of the accelerated Twinrix 4 dose vaccine series.	06/23/1990	F	057	Public safety worker exposed to blood or infection body fluids								Complete	05/17/2016	Hep B	104	SKB	Valid	risk		05/24/2016	Hep B	104	SKB	Valid	risk		06/07/2016	Hep B	104	SKB	Valid	risk		06/17/2017	Hep B, Adult	104
2016-UC-0045	Patient is 50 years of age unvaccinated and is on dialysis.	01/17/1966	M	032	Dialysis patient								Not Complete																							
2016-UC-0046	Patient is on dialysis and has received the first dose of the Hep B risk Recombivax 3 dose series vaccine.	01/17/1966	M	032	Dialysis patient								Not Complete	04/22/2016	Hep B, Dialysis	44	MSD	Valid	risk																	
2016-UC-0047	Patient is on dialysis and has received the second dose of the Hep B risk Recombivax 3 dose series vaccine.	01/17/1966	M	032	Dialysis patient								Not Complete	04/22/2016	Hep B, Dialysis	44	MSD	Valid	risk		05/20/2016	Hep B, Dialysis	44	MSD	Valid	risk										
2016-UC-0048	Patient is on dialysis, and has received all three doses of the Hep B risk Recombivax 3 dose series vaccine.	04/30/1953	F	032	Dialysis patient								Complete	05/15/2016	Hep B, Dialysis	44	MSD	Valid	risk		06/12/2016	Hep B, Dialysis	44	MSD	Valid	risk		11/12/2016	Hep B, Dialysis	44	MSD	Valid	risk				
2016-UC-0049	Patient is 69 years of age, unvaccinated with Hep B, and is on dialysis.	02/13/1947	F	032	Dialysis patient								Not Complete																							
2016-UC-0050	Patient is on dialysis and has received the first dose of the Hep B risk Engerix- B 4-dose series.	02/13/1947	F	032	Dialysis patient								Not Complete	03/13/2016	Hep B, Adult	43	SKB	Valid	risk																	
2016-UC-0051	Patient is on dialysis, and has received the second dose of the Hep B risk Engerix- B 4- dose series.	02/13/1947	F	032	Dialysis patient								Not Complete	03/13/2016	Hep B, Adult	43	SKB	Valid	risk		04/10/2016	Hep B, Adult	43	SKB	Valid	risk										
2016-UC-0052	Patient is on dialysis, and has received the third dose of the Hep B risk Engerix- B 4- dose series.	02/13/1947	F	032	Dialysis patient								Not Complete	03/13/2016	Hep B, Adult	43	SKB	Valid	risk		04/10/2016	Hep B, Adult	43	SKB	Valid	risk		05/08/2016	Hep B, Adult	43	SKB	Valid	risk				
2016-UC-0053	Patient is on dialysis and has received all four doses of the Hep B risk Engerix- B 4-dose series.	02/13/1947	F	032	Dialysis patient								Complete	03/13/2016	Hep B, Adult	43	SKB	Valid	risk		04/10/2016	Hep B, Adult	43	SKB	Valid	risk		05/08/2016	Hep B, Adult	43	SKB	Valid	risk		09/08/2016	Hep B, Adult	43
2016-UC-0054	Patient is 2 years of age, has anatomical or functional asplenia, and has not received any prior doses of the Hib vaccine.	07/15/2014	F	160	Anatomical or functional asplenia								Not Complete																							

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0055	Patient is 2 years of age and has anatomical or functional asplenia and has received one dose of the Hib Risk 2 dose series vaccine.	07/15/2014	F	160	Anatomical or functional asplenia								Not Complete	08/15/2016	PRP-T	48	PMC	Valid	standard																		
2016-UC-0056	Patient is 2 years of age and has anatomical or functional asplenia and has received the second dose of the Hib Risk 2 dose series.	07/15/2014	F	160	Anatomical or functional asplenia								Complete	08/08/2016	PRP-T	48	PMC	Valid	standard		10/03/2016	PRP-T	48	PMC	Valid	risk											
2016-UC-0057	Patient is 24 months of age, has Persistent complement, properdin, or factor B deficiency and has received only one dose of the Hib vaccine before 12 months of age.	08/10/2014	F	151	Persistent complement, properdin, or factor B deficiency								Not Complete	01/10/2015	PRP-OMP	49	MSD	Valid	standard																		
2016-UC-0058	Patient is a child that has Persistent complement, properdin, or factor B deficiency and has received one dose of the Hib standard vaccine before 12 months of age, and one dose of the Hib risk child 2 dose series vaccine.	08/10/2014	F	151	Persistent complement, properdin, or factor B deficiency								Not Complete	01/10/2015	PRP-OMP	49	MSD	Valid	standard		04/13/2016	PRP-OMP	49	MSD	Valid	risk											
2016-UC-0059	Patient is a child that has Persistent complement, properdin, or factor B deficiency and has received one dose of the Hib standard vaccine before 12 months of age, and two doses of the Hib risk child 2 dose series vaccine.	08/10/2014	F	151	Persistent complement, properdin, or factor B deficiency								Complete	01/10/2015	PRP-OMP	49	MSD	Valid	standard		04/13/2016	PRP-OMP	49	MSD	Valid	risk		06/08/2016	PRP-OMP	49	MSD	Valid	risk				
2016-UC-0060	Patient is 36 months of age, has anatomical or functional asplenia and has received two dose of the Standard Hib vaccine before 12 months of age.	04/22/2013	M	160	Anatomical or functional asplenia								Not Complete	06/10/2013	PRP-T	48	PMC	Valid	standard		07/08/2013	PRP-T	48	PMC	Valid	standard											
2016-UC-0061	Patient is 36 months of age, has anatomical or functional asplenia and has received two previous doses of the Standard Hib vaccine before 12 months of age and a dose of the Hib risk child 2 dose series vaccine.	04/22/2013	M	160	Anatomical or functional asplenia								Complete	06/10/2013	PRP-T	48	PMC	Valid	standard		07/08/2013	PRP-T	48	PMC	Valid	standard		05/14/2016	PRP-T	48	PMC	Valid	risk				
2016-UC-0062	Patient is 7 years of age, has not received any Hib vaccine, and is undergoing elective splenectomy.	06/22/2009	M	002	Undergoing elective splenectomy								Not Complete																								
2016-UC-0063	Patient is 7 years and is undergoing elective splenectomy and has received the one dose Hib risk 1 dose series	06/22/2009	M	002	Undergoing elective splenectomy								Complete	07/01/2016	PRP-OMP	49	MSD	Valid	risk																		
2016-UC-0064	Patient is 19 years of age is undergoing elective splenectomy and has no history of receiving Hib vaccine	07/10/1997	F	002	Undergoing elective splenectomy								Not Complete																								

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0065	Patient is 19 years of age and undergoing elective splenectomy and has received the Hib risk 1 dose series	07/10/1997	F	002	Undergoing elective splenectomy								Complete	08/03/2016	PRP-OMP	49	MSD	Valid	risk																		
2016-UC-0066	Patient is 12 years of age, has HIV infection, and unvaccinated with Hib vaccine	04/23/2003	F	155	HIV/AIDS - not severely immunocompromised								Not Complete																									
2016-UC-0067	Patient is 12 years of age, has HIV infection, and has received the Hib risk 1 dose series.	04/23/2003	F	155	HIV/AIDS - not severely immunocompromised								Complete	02/03/2016	PRP-OMP	49	MSD	Valid	risk																		
2016-UC-0068	Patient is 4 years of age, a recipient of a successful hematopoietic stem cell transplant 6 months ago.	08/14/2010	M	004	Recipient of a hematopoietic stem cell transplant								Not Complete																									
2016-UC-0069	Patient is a child that is a recipient of a successful hematopoietic stem cell transplant and has a dose of the Hib vaccine.	08/14/2010	M	004	Recipient of a hematopoietic stem cell transplant								Not Complete	09/19/2014	PRP-T	48	PMC	Valid	standard																		
2016-UC-0070	Patient is a child and a recipient of a successful hematopoietic stem cell transplant and has received two doses of the Hib risk 3-dose series.	04/09/2006	M	004	Recipient of a hematopoietic stem cell transplant								Not Complete	09/19/2014	PRP-T	48	PMC	Valid	standard		10/17/2014	PRP-T	48	PMC	Valid	risk											
2016-UC-0071	Patient is a child is a recipient of a successful hematopoietic stem cell transplant, and has received all three doses of the Hib risk 3 dose series 6 to 12 months post operation.	05/28/2004	M	004	Recipient of a hematopoietic stem cell transplant								Complete	06/01/2014	PRP-T	48	PMC	Valid	standard		06/29/2014	PRP-T	48	PMC	Valid	risk		07/27/2014	PRP-T	48	PMC	Valid	risk			
2016-UC-0072	Patient is 20 years of age and is a recipient of a successful hematopoietic stem cell transplant and has not receive recommended doses of the HIB vaccine.	05/13/1996	M	004	Recipient of a hematopoietic stem cell transplant								Not Complete																									
2016-UC-0073	Patient is an adult recipient of a successful hematopoietic stem cell transplant, and has received the first dose of the Hib Risk 3 dose series.	05/13/1996	M	004	Recipient of a hematopoietic stem cell transplant								Not Complete	07/25/2016	PRP-T	48	PMC	Valid	risk																		
2016-UC-0074	Patient is an adult recipient of a successful hematopoietic stem cell transplant, and has received the second dose of the Hib Risk 3 dose series.	05/13/1996	M	004	Recipient of a hematopoietic stem cell transplant								Not Complete	07/25/2016	PRP-T	48	PMC	Valid	risk		08/22/2016	PRP-T	48	PMC	Valid	risk											
2016-UC-0075	Patient is a adult recipient of a successful hematopoietic stem cell transplant, and has received all three doses of the Hib Risk 3 dose series.	05/13/1996	M	004	Recipient of a hematopoietic stem cell transplant								Complete	07/25/2016	PRP-T	48	PMC	Valid	risk		08/22/2016	PRP-T	48	PMC	Valid	risk		09/19/2016	PRP-T	48	PMC	Valid	risk			
2016-UC-0076	Patient is 9 years of age, female, has a history of sexual abuse/assault and has not received the HPV vaccine.	04/04/2007	F	169	History of sexual abuse or assault								Not Complete																									
2016-UC-0077	Patient is a 9 years of age, female, has a history of sexual abuse/assault, and has received the first dose of the HPV vaccine.	04/04/2007	F	169	History of sexual abuse or assault								Not Complete	12/15/2016	9vHPV	165	MSD	Valid	standard																		
2016-UC-0078	Patient is 10 years of age, female, has a history of sexual abuse/assault, and has received the second dose of the HPV risk female 2 dose series at 5 months.	06/30/2006	F	169	History of sexual abuse or assault								Complete	08/05/2016	9vHPV	165	MSD	Valid	standard		01/05/2017	9vHPV	165	MSD	Valid	risk											

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0079	Patient is 11 years of age, female, has a history of sexual abuse/assault, and has received two doses of the HPV risk female 2 dose series	03/03/2005	F	169	History of sexual abuse or assault								Complete	12/19/2016	9vHPV	165	MSD	Valid	standard		06/01/2017	9vHPV	165	MSD	Valid	risk											
2016-UC-0080	Patient is 9 years of age, male, has a history of sexual abuse/assault, and has not received the HPV vaccine.	02/15/2007	M	169	History of sexual abuse or assault								Not Complete																								
2016-UC-0083	Patient is 10 years of age, male, has a history of T-Lymphocyte , and has received three doses of the HPV risk male 3 dose series vaccine.	03/13/2006	M	148	T-lymphocyte (cell-mediated and humoral) - Partial defects								Complete	05/17/2016	9vHPV	165	MSD	Valid	standard		06/14/2016	9vHPV	165	MSD	Valid	risk		11/01/2016	9vHPV	165	MSD	Valid	risk				
2016-UC-0084	Patient is 11 years of age, male, has a history of sexual abuse/assault, and has received the 2nd dose of the Risk Male 2 dose HPV vaccine at 4 weeks.	01/13/2007	M	169	History of sexual abuse or assault								Not Complete	04/21/2016	9vHPV	165	MSD	Valid	standard		05/19/2016	9vHPV	165	MSD	Valid	risk											
2016-UC-0085	Patient is an adult male, MSM, and has no previous history of the HPV vaccine.	02/02/1994	M	036	Men who have sex with men								Not Complete																								
2016-UC-0086	Patient is an adult male, MSM, and has received his first dose of the HPV vaccine.	02/02/1994	M	036	Men who have sex with men								Not Complete	07/21/2016	9vHPV	165	MSD	Valid	standard																		
2016-UC-0087	Patient is an adult male, MSM, and has received the second dose of the HPV risk adult male 3 dose series	01/23/1988	M	036	Men who have sex with men								Not Complete	04/03/2014	4vHPV	062	MSD	Valid	standard		05/01/2014	4vHPV	062	MSD	Valid	risk											
2016-UC-0088	Patient is an adult male, MSM, and has received all three doses of the HPV risk adult male 3-dose series.	03/01/1990	M	036	Men who have sex with men								Complete	03/28/2015	4vHPV	062	MSD	Valid	standard		04/25/2015	4vHPV	062	MSD	Valid	risk		09/14/2015	4vHPV	62	MSD	Valid	risk				
2016-UC-0089	Patient is 32 years of age and plans on traveling to an endemic area (for longer than a month) with Japanese encephalitis.	07/01/1984	F	165	Longer-term (e.g., 1 month or more) travel to a JE-endemic area								Not Complete																								
2016-UC-0090	Patient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month, and has received the first dose of the Japanese Encephalitis risk 2 dose series vaccine.	07/01/1984	F	165	Longer-term (e.g., 1 month or more) travel to a JE-endemic area								Not Complete	08/15/2016	Japanese Encephalitis, VC	134	VAL	Valid	risk																		

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0091	Patient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month, and has received the second dose of the Japanese Encephalitis risk 2 dose series vaccine.	09/10/1983	M	165	Longer-term (e.g., 1 month or more) travel to a JE-endemic area								Not Complete	04/28/2016	Japanese Encephalitis, VC	134	VAL	Valid	risk		05/25/2016	Japanese Encephalitis, VC	134	VAL	Valid	risk											
2016-UC-0092	Patient is 6 months of age and plans to travel with parent from the U.S. for international travel and has not received the Measles (MMR) vaccine.	02/28/2016	F	048	Travelling Internationally								Not Complete																								
2016-UC-0093	Patient is 6 months of age and is still traveling with parents from the U.S. for international travel and has received the Measles (MMR) risk 1-dose vaccine series.	02/28/2016	F	048	Travelling Internationally								Not Complete	08/28/2016	MMR	03	MSD	Valid	risk																		
2016-UC-0094	Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy	05/12/1996	F	026	Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]	120	Begin Date of antiviral therapy [ART]	06/12/2016					Not Complete	05/12/1997	MMR	03	MSD	Valid	standard		05/12/2000	MMR	03	MSD	Valid	standard											
2016-UC-0095	Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy who has received his first dose of the second round of MMR vaccines.	05/12/1996	F	026	Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]	120	Begin Date of antiviral therapy [ART]	06/12/2016					Not Complete	05/12/1997	MMR	03	MSD	Valid	standard		05/12/2000	MMR	03	MSD	Valid	standard		12/12/2016	MMR	03	MSD	Valid	risk				
2016-UC-0096	Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy and has received the second dose of the second round of MMR vaccine.	05/12/1996	F	026	Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]	120	Begin Date of antiviral therapy [ART]	06/12/2016					Complete	05/12/1997	MMR	03	MSD	Valid	standard		05/12/2000	MMR	03	MSD	Valid	standard		12/12/2016	MMR	03	MSD	Valid	risk		01/12/2017	MMR	03
2016-UC-0097	Patient is 12 years of age and is seeking protection against strains of Men B disease.	07/04/1998	M	001	Patient seeks protection								Not Complete																								
2016-UC-0098	Patient is 12 years of age and is seeking protection against strains of Men B disease and has received the first dose of the Men B series.	07/04/1998	M	001	Patient seeks protection								Not Complete	07/04/2016	meningococcal B, OMV	163	PFR	Valid	risk																		
2016-UC-0099	Patient is 12 years of age and is seeking protection against strains of Men B disease and has received the second dose of the Men B dose vaccine series.	07/04/1998	M	001	Patient seeks protection								Complete	07/04/2016	meningococcal B, OMV	163	PFR	Valid	risk		01/04/2017	meningococcal B, OMV	163	PFR	Valid	risk											

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0100	Patient is 10 years of age, has anatomical or functional asplenia and has not received the Meningococcal B vaccine.	03/28/2006	M	160	Anatomical or functional asplenia								Not Complete																									
2016-UC-0101	Patient is 10 years of age, has anatomical or functional asplenia, and has received the first dose of the Men B risk 2-dose vaccine.	03/28/2006	M	160	Anatomical or functional asplenia								Not Complete	03/28/2016	meningococcal B, OMV	163	NOV	Valid	risk																			
2016-UC-0103	Patient is a microbiologist routinely exposed to Neisseria Meningitidis.	10/01/1976	F	050	Microbiologists routinely exposed to Neisseria meningitidis								Not Complete																									
2016-UC-0104	Patient is a microbiologist routinely exposed to Neisseria Meningitidis and has received the first dose of the Men B vaccine	10/01/1976	F	050	Microbiologists routinely exposed to Neisseria meningitidis								Not Complete	06/23/2016	meningococcal B, recombinant	162	PFR	Valid	risk																			
2016-UC-0105	Microbiologist routinely exposed to Neisseria Meningitidis and has received the second dose of the Men B risk 3 dose series	10/01/1976	F	050	Microbiologists routinely exposed to Neisseria meningitidis								Not Complete	06/23/2016	meningococcal B, recombinant	162	PFR	Valid	risk		07/21/2016	meningococcal B, recombinant	162	PFR	Valid	risk											
2016-UC-0107	8 week old infant with anatomical or functional asplenia and has not received Meningococcal vaccine.	02/14/2015	M	160	Anatomical or functional asplenia								Not Complete																									
2016-UC-0108	7 week old infant with functional asplenia and has received the first dose of the Meningococcal ACWY risk start before 7 months series.	02/14/2015	M	160	Anatomical or functional asplenia								Not Complete	04/14/2015	Meningococcal, MCV4O	136	NOV	Valid	risk																			
2016-UC-0109	7 week old infant with functional asplenia and has received the second dose of the Meningococcal ACWY risk start before 7 months series.	02/14/2015	M	160	Anatomical or functional asplenia								Not Complete	04/14/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		06/09/2015	Meningococcal, MCV4O	136	NOV	Valid	risk											
2016-UC-0110	7 week old infant with functional asplenia and has receive the third dose of the Meningococcal ACWY risk start before 7 months 4-dose series.	02/14/2015	M	160	Anatomical or functional asplenia								Not Complete	04/14/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		06/09/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		08/04/2015	Meningococcal, MCV4O	136	NOV	Valid	risk				
2016-UC-0111	7 week old infant with functional asplenia and has received all four doses of the Meningococcal ACWY risk start before 7 months series.	02/14/2015	M	160	Anatomical or functional asplenia								Not Complete	04/14/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		06/09/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		08/04/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		02/14/2016	Meningococcal, MCV4O	136
2016-UC-0112	4 month old 4 year old child who has functional asplenia, has completed the primary doses, and has received the first booster dose at 3 years later.	08/23/2012	M	160	Anatomical or functional asplenia								Not Complete	10/23/2012	Meningococcal, MCV4O	136	NOV	Valid	risk		12/18/2012	Meningococcal, MCV4O	136	NOV	Valid	risk		02/12/2013	Meningococcal, MCV4O	136	NOV	Valid	risk		08/23/2013	Meningococcal, MCV4O	136
2016-UC-0113	4 month old 4 year old child who has functional asplenia and has received the 3 year booster dose as well as the 5 year booster dose of the Meningococcal ACWY risk start before 7 months series.	01/01/2007	M	160	Anatomical or functional asplenia								Not Complete	03/01/2007	Meningococcal, MCV4O	136	NOV	Valid	risk		04/26/2007	Meningococcal, MCV4O	136	NOV	Valid	risk		06/21/2007	Meningococcal, MCV4O	136	NOV	Valid	risk		01/01/2008	Meningococcal, MCV4O	136

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0114	7 month old infant (with no previous history of Meningococcal vaccine) at risk for Meningococcal disease during a community outbreak.	05/10/2015	F	070	Persons at risk during an outbreak								Not Complete																							
2016-UC-0115	Patient is a 7 month old infant and is at risk during a community outbreak of Meningococcal disease and has received the first dose of the Meningococcal ACWY risk start after 7 months 2 dose vaccine.	05/10/2015	F	070	Persons at risk during an outbreak								Not Complete	12/10/2015	Meningococcal, MCV4O	136	NOV	Valid	risk																	
2016-UC-0116	Patient is a 12 months old and was at risk during a community outbreak of Meningococcal disease and has received the second dose of the Meningococcal ACWY risk start after 7 months 2 dose vaccine.	05/10/2015	F	070	Persons at risk during an outbreak								Not Complete	12/10/2015	Meningococcal, MCV4O	136	NOV	Valid	risk		05/10/2016	Meningococcal, MCV4O	136		Valid	risk										
2016-UC-0117	7 month old infant, with persistent complement deficiencies, and has not received any Meningococcal vaccine.	07/28/2015	M	151	Persistent complement, properdin, or factor B deficiency								Not Complete																							
2016-UC-0123	Adult with no known history of meningococcal vaccination and has anatomical or functional asplenia	04/18/1992	M	160	Anatomical or functional asplenia								Not Complete																							
2016-UC-0124	Patient is an adult with anatomical or functional asplenia and has received the first dose of the Meningococcal ACWY risk 2 dose series vaccine	04/18/1992	M	160	Anatomical or functional asplenia								Not Complete	05/02/2016	Meningococcal, MCV4O	136	NOV	Valid	risk																	
2016-UC-0125	Patient is an adult with anatomical or functional asplenia and has received the second dose of the Meningococcal ACWY risk 2 dose series vaccines.	04/18/1992	M	160	Anatomical or functional asplenia								Not Complete	05/02/2016	Meningococcal, MCV4O	136	NOV	Valid	risk		06/27/2016	Meningococcal, MCV4O	136	NOV	Valid	risk										
2016-UC-0127	Patient is a first year college student living in a residence hall and has received the Meningococcal ACWY risk 1 dose series.	01/17/1997	F	046	College students living in residence halls								Complete	01/17/2016	Meningococcal, MCV4P	114	PMC	Valid	risk																	
2016-UC-0128	Patient is 60 years of age (vaccine naive) and at risk during a Meningococcal outbreak.	03/07/1956	M	070	Persons at risk during an outbreak								Not Complete																							
2016-UC-0129	Patient is 60 years of age, at risk during a Meningococcal outbreak, and has received the Meningococcal risk 1 dose vaccine.	03/07/1956	M	070	Persons at risk during an outbreak								Not Complete	05/23/2016	Meningococcal, MPSV4	32	PMC	Valid	risk																	
2016-UC-0130	Patient is pregnant, and at 27 weeks of gestation, and has not received the Pertussis vaccine (Tdap)	06/23/1988	F	007	Pregnant		170	Onset of pregnancy	08/22/2016				Not Complete																							
2016-UC-0131	Patient is pregnant, at 27 weeks of gestation, and has received a Tdap	06/23/1988	F	007	Pregnant		170	Onset of pregnancy	08/22/2016				Complete	03/01/2017	Tdap	115	SKB	Valid	risk																	
2016-UC-0132	Laboratory worker who handles specimens that might contain Polio and has completed a Polio standard series, but has not received any additional doses.	11/23/1977	M	054	Laboratory workers who handle specimens that might contain polioviruses								Not Complete	01/23/1978	IPV	10	PMC	Valid	standard		02/20/1978	IPV	10	PMC	Valid	standard		11/23/1978	IPV	10	PMC	Valid	standard		02/02/1982	IPV	10

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0133	Patient is a laboratory worker who handles specimens that might contain Polio and has completed a Polio standard dose series and the additional risk dose. Patient is 39 years of age, with no previous history of the polio vaccine, and plans on traveling to areas or countries where polio is endemic.	11/23/1977	M	054	Laboratory workers who handle specimens that might contain polioviruses								Complete	01/23/1978	IPV	10	PMC	Valid	standard		02/20/1978	IPV	10	PMC	Valid	standard		11/23/1978	IPV	10	PMC	Valid	standard		02/02/1982	IPV	10
2016-UC-0134		08/10/1961	F	143	Travel to areas or countries where polio is epidemic or endemic								Not Complete																								
2016-UC-0135	Patient is traveling to areas or countries where polio is endemic and has received the first dose of the polio risk adult vaccine.	08/10/1961	F	143	Travel to areas or countries where polio is epidemic or endemic								Not Complete	09/05/2016	IPV	10	PMC	Valid	risk																	
2016-UC-0136	Patient is traveling to areas or countries where polio is endemic and has received the second dose of the polio risk adult vaccine.	08/10/1961	F	143	Travel to areas or countries where polio is epidemic or endemic								Not Complete	09/05/2016	IPV	10	PMC	Valid	risk		10/03/2016	IPV	10	PMC	Valid	risk											
2016-UC-0137	Patient is traveling to areas or countries where polio is an epidemic and has received all three doses of the polio risk adult vaccine.	08/10/1961	F	143	Travel to areas or countries where polio is epidemic or endemic								Complete	09/05/2016	IPV	10	PMC	Valid	risk		10/03/2016	IPV	10	PMC	Valid	risk		04/03/2017	IPV	10	PMC	Valid	risk				
2016-UC-0138	Patient is a Rabies Researcher with previous history of Rabies vaccine, but has been tested and found to have a fallen serum titer.	02/16/1982	F	053	Rabies researchers								Not Complete	06/28/2015	Rabies, intramuscular injection	175	NOV	Valid	risk		07/05/2015	Rabies, intramuscular injection	175	NOV	Valid	risk		07/19/2015	Rabies, intramuscular injection	175	NOV	Valid	risk				
2016-UC-0139	Patient is a Rabies Researcher with previous history of Rabies vaccine, but has a confirmed test of a fallen serum titer and has received a booster dose of the Rabies risk 3-dose continuous series.	02/16/1982	F	053	Rabies researchers								Not Complete	06/28/2015	Rabies, intramuscular injection	175	NOV	Valid	risk		07/05/2015	Rabies, intramuscular injection	175	NOV	Valid	risk		07/19/2015	Rabies, intramuscular injection	175	NOV	Valid	risk		01/19/2016	Rabies, intramuscular injection	175
2016-UC-0140	New Rabies Researcher with no previous history of the Rabies vaccine.	09/21/1986	M	053	Rabies researchers								Not Complete																								
2016-UC-0141	Patient is a new Rabies Researcher and has received the first dose of the Rabies risk 3-dose continuous vaccine series.	09/21/1986	M	053	Rabies researchers								Not Complete	05/16/2016	Rabies, intramuscular injection	175	PMC	Valid	risk																	
2016-UC-0142	Patient is a new Rabies Researcher and has received the second dose of the Rabies risk 3-dose continuous vaccine series.	09/21/1986	M	053	Rabies researchers								Not Complete	05/16/2016	Rabies, intramuscular injection	175	PMC	Valid	risk		05/23/2016	Rabies, intramuscular injection	175	PMC	Valid	risk											
2016-UC-0143	Patient is a new Rabies Researcher and has received all three doses of the Rabies risk 3-dose continuous vaccine series.	09/21/1986	M	053	Rabies researchers								Not Complete	05/16/2016	Rabies, intramuscular injection	175	PMC	Valid	risk		05/23/2016	Rabies, intramuscular injection	175	PMC	Valid	risk		06/06/2016	Rabies, intramuscular injection	175	PMC	Valid	risk				
2016-UC-0144	Patient is an animal handler with previous history of the Rabies vaccine but has been tested and found to have a fallen serum titer.	01/12/1990	F	061	Animal handlers								Not Complete	06/18/2015	Rabies, intramuscular injection	175	PMC	Valid	risk		06/25/2015	Rabies, intramuscular injection	175	PMC	Valid	risk		07/09/2015	Rabies, intramuscular injection	175	PMC	Valid	risk				

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0145	Animal handler with previous history of the Rabies vaccine but has been tested and found to have a fallen serum titer and has received the booster dose of the Rabies risk 3 dose frequent series.	01/12/1990	F	061	Animal handlers								Not Complete	06/18/2015	Rabies, intramuscular injection	175	PMC	Valid	risk		06/25/2015	Rabies, intramuscular injection	175	PMC	Valid	risk		07/09/2015	Rabies, intramuscular injection	175	PMC	Valid	risk		07/19/2017	Rabies, intramuscular injection	175
2016-UC-0146	Patient is 46 years of age and travelling to an area at risk of exposure to S. Typhi.	04/19/1970	M	163	Travel to areas in which there is a recognized risk of exposure to S. typhi								Not Complete																								
2016-UC-0147	Patient is traveling to an area at risk of exposure to S. Typhi and has received the Typhoid risk 1 dose vaccine series two weeks before potential exposure.	04/19/1970	M	163	Travel to areas in which there is a recognized risk of exposure to S. typhi								Not Complete	07/22/2016	Typhoid capsular polysaccharide	101	PMC	Valid	risk																		
2016-UC-0148	Two years later, patient continues to travel to an area at risk of exposure to S. Typhi and has received the booster dose of the Typhoid risk 1-dose series.	04/19/1970	M	163	Travel to areas in which there is a recognized risk of exposure to S. typhi								Not Complete	07/22/2016	Typhoid capsular polysaccharide	101	PMC	Valid	risk		07/22/2018	Typhoid capsular polysaccharide	101	PMC	Valid	risk											
2016-UC-0149	Microbiology laboratorian who works frequently with S. typhi carrier and has not received the Typhoid vaccine.	10/15/1980	M	051	Microbiology laboratorians who work frequently with S. typhi								Not Complete																								
2016-UC-0150	Patient is a microbiology laboratorian who works frequently with S. typhi carrier and has received the Typhoid vaccine.	10/15/1980	M	051	Microbiology laboratorians who work frequently with S. typhi								Not Complete	08/16/2016	Typhoid oral, live, attenuated	25	PMC	Valid	risk																		
2016-UC-0151	Patient is 52 years of age and travelling to a country at risk for Yellow Fever transmission.	07/01/1964	F	162	Travel to areas at risk for Yellow Fever transmission								Not Complete																								
2016-UC-0152	Patient is travelling to a country at risk for Yellow Fever transmission and has received the Yellow Fever risk 1 dose series.	07/01/1964	F	162	Travel to areas at risk for Yellow Fever transmission								Complete	09/01/2016	Yellow Fever	37	PMC	Valid	risk																		

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0153	Patient is 3 years old with cochlear implants, and has an incomplete schedule (only received 1 dose at 4 months) of the PCV 13 series.	01/08/2013	M	011	Cochlear implants								Not Complete	05/08/2013	PCV 13	133	PFR	Valid	standard																	
2016-UC-0154	Patient is 3 years old with cochlear implants, has received one standard dose of the PCV 13 series and has received the first dose of the risk 2-5 years 3 dose series.	01/08/2013	M	011	Cochlear implants								Not Complete	05/08/2013	PCV 13	133	PFR	Valid	standard		02/12/2016	PCV 13	133	PFR	Valid	risk										
2016-UC-0155	Patient is 4 years old with cochlear implants, and has received one standard dose of the PCV 13 series and has received the second dose of the risk 2-5 years 3 dose series.	01/08/2013	M	011	Cochlear implants								Not Complete	05/08/2013	PCV 13	133	PFR	Valid	standard		02/12/2016	PCV 13	133	PFR	Valid	risk		04/08/2016	PCV 13	133		Valid	Risk				
2016-UC-0156	Patient is 4 years old with cochlear implants, has received three doses of the PCV13 vaccine, and one dose of the PPSV23 vaccine.	05/17/2012	M	011	Cochlear implants								Not Complete	09/27/2012	PCV 13	133	PFR	Valid	standard		12/13/2012	PCV 13	133	PFR	Valid	risk		05/17/2013	PCV 13	133	PFR or WAL	Valid	risk		05/21/2016	PPSV23	33
2016-UC-0157	Patient is 19 years of age and smokes cigarettes and has not received the PPSV23 vaccine.	03/08/1997	F	042	Smoke cigarettes								Not Complete																								
2016-UC-0158	Patient is 19 years of age, smokes cigarettes and has received the Pneumococcal risk 1 dose vaccine.	03/08/1997	F	042	Smoke cigarettes								Not Complete	04/16/2016	PPSV23	33	MSD	Valid	risk																	
2016-UC-0159	Child is 8 years of age with cerebrospinal fluid leaks and has not received (vaccine naive)PCV13 nor PPSV23 vaccine.	09/14/2008	M	010	Cerebrospinal fluid leaks								Not Complete																								
2016-UC-0160	Patient is 8 years of age and has cerebrospinal fluid leaks and has received the PCV13 vaccine but not the PPSV23 vaccine.	09/14/2008	M	010	Cerebrospinal fluid leaks								Not Complete	09/14/2016	PCV 13	133	PFR	Valid	risk																	
2016-UC-0161	Patient is 8 years of age, has cerebrospinal fluid leaks and has received a dose of the PCV 13 and a dose of the PPSV23 vaccine.	09/14/2008	M	010	Cerebrospinal fluid leaks								Not Complete	09/14/2016	PCV 13	133	PFR	Valid	risk		11/09/2016	PPSV 23	33	MSD	Valid	risk										
2016-UC-0162	Patient is 15 years of age and has cerebrospinal fluid leaks and has received a dose of the PPSV23 vaccine but not the PCV13 vaccine.	03/16/2001	F	010	Cerebrospinal fluid leaks								Not Complete	05/02/2016	PPSV 23	33	MSD	Valid	risk																	
2016-UC-0163	Patient is 15 years of age and has cerebrospinal fluid leaks and has received the second dose of the Pneumococcal risk 2-dose PPSV-PCV series vaccine.	03/16/2001	F	010	Cerebrospinal fluid leaks								Not Complete	05/02/2016	PPSV 23	33	MSD	Valid	risk		06/27/2016	PCV 13	133	PFR	Valid	risk										
2016-UC-0164	Patient is 39 years of age, has cochlear implants, and has received the PPSV23 vaccine but not PCV13.	05/01/1977	M	011	Cochlear implants								Not Complete	08/01/2016	PPSV 23	33	MSD	Valid	risk																	
2016-UC-0165	Patient is 39 years of age, has cochlear implants, has received the PCV13 vaccine one year after the PPSV23 vaccine dose.	05/01/1977	M	011	Cochlear implants								Not Complete	08/01/2016	PPSV 23	33	MSD	Valid	risk		08/01/2017	PCV 13	133	PFR	Valid	risk										

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0166	Patient is a two year old child with sickle cell disease, who has completed the PCV 13 vaccine standard series but has not received a dose of the PPSV 23 vaccine.	03/21/2010	F	160	Anatomical or functional asplenia								Not Complete	05/21/2010	PCV 13	133	PFR	Valid	standard		07/21/2010	PCV 13	133	PFR	Valid	standard		09/21/2010	PCV 13	133	PFR	Valid	standard		05/21/2012	PCV 13	133
2016-UC-0167	Patient is 9 years of age, has sickle cell disease, has completed the PCV 13 standard vaccine series, and has received a dose of PPSV23 series.	03/21/2010	F	160	Anatomical or functional asplenia								Not Complete	05/21/2010	PCV 13	133	PFR	Valid	standard		07/21/2010	PCV 13	133	PFR	Valid	standard		09/21/2010	PCV 13	133	PFR	Valid	standard		05/21/2012	PCV 13	133
2016-UC-0168	Patient is now 11 years of age, has sickle cell disease, has completed the PCV 13 standard vaccine series, received the first and 5 year booster dose of PPSV23 series.	03/21/2010	F	160	Anatomical or functional asplenia								Not Complete	05/21/2010	PCV 13	133	PFR	Valid	standard		07/21/2010	PCV 13	133	PFR	Valid	standard		09/21/2010	PCV 13	133	PFR	Valid	standard		05/21/2011	PCV 13	133
2016-UC-0169	Patient is 9 years of age, has HIV infection, and has only received a dose of PPSV23 vaccine but has not received a dose of the PCV 13 vaccine.	04/13/2007	M	155	HIV/AIDS - not severely immunocompromised								Not Complete	06/01/2016	PPSV 23	33	MSD	Valid	risk																		
2016-UC-0170	Patient is 9 years of age, has HIV infection, and has received a dose of PPSV23 vaccine and a dose of the PCV 13 vaccine 8 weeks later.	04/13/2007	M	155	HIV/AIDS - not severely immunocompromised								Not Complete	06/01/2016	PPSV 23	33	MSD	Valid	risk		07/27/2016	PCV 13	133	PFR	Valid	risk											
2016-UC-0171	Patient is now 14 years of age, has HIV infection, and has received two doses (one is booster dose 5 years later) of PPSV23 and a dose of PCV13.	04/13/2007	M	155	HIV/AIDS - not severely immunocompromised								Not Complete	06/01/2016	PPSV 23	33	MSD	Valid	risk		07/27/2016	PCV 13	133	PFR	Valid	risk		06/01/2021	PPSV 23	33	MSD	Valid	Risk				
2016-UC-0172	Patient is 22 years of age and has General malignant neoplasm and has received a dose of PPSV23 but not PCV13.	06/13/1994	M	156	Generalized malignant neoplasm								Not Complete	08/21/2016	PPSV 23	33	MSD	Valid	risk																		
2016-UC-0173	Patient is 22 years of age with General malignant neoplasm and has received a dose of PPSV23 and a dose PCV13 at a year later.	06/13/1994	M	156	Generalized malignant neoplasm								Not Complete	08/21/2016	PPSV 23	33	MSD	Valid	risk		08/21/2017	PCV 13	133	PFR	Valid	risk											
2016-UC-0174	Patient is 27 years of age and has General malignant neoplasm, has received a 2 doses of PPSV23, and a dose of PCV13.	06/13/1994	M	156	Generalized malignant neoplasm								Not Complete	08/21/2016	PPSV 23	33	MSD	Valid	risk		08/21/2017	PCV 13	133	PFR	Valid	risk		08/21/2022	PPSV 23	33	MSD	Valid	risk				
2016-UC-0175	Patient is 14 years of age and has Persistent Component, properdin, or Factor B deficiency, has previously received 2 doses of the PPSV23 vaccine but has not received a dose of PCV13.	04/04/2002	F	151	Persistent complement, properdin, or factor B deficiency								Not Complete	04/16/2011	PPSV 23	33	MSD	Valid	risk		04/16/2016	PPSV 23	33	MSD	Valid	risk											

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0176	years of age and has Persistent Component, properdin, or Factor B deficiency, has previously received 2 doses of the PPSV23 vaccine and has received a dose of PCV13 vaccine 8 weeks later.	04/04/2002	F	151	Persistent complement, properdin, or factor B deficiency								Not Complete	04/16/2011	PPSV 23	33	MSD	Valid	risk		04/16/2016	PPSV 23	33	MSD	Valid	risk		06/11/2016	PCV 13	133	PFR	Valid	Risk				
2016-UC-0177	Patient is 25 years of age with nephrotic syndrome, has previously received two doses of PPSV23 vaccine but has not received a dose of the PCV13 vaccine.	07/02/1986	M	167	Nephrotic Syndrome								Not Complete	08/03/2006	PPSV 23	33	MSD	Valid	risk		08/03/2011	PPSV 23	33	MSD	Valid	risk											
2016-UC-0178	Patient has nephrotic syndrome, has received two doses of the PPSV vaccine and a dose of the PCV13 vaccine	07/02/1986	M	167	Nephrotic Syndrome								Not Complete	08/03/2006	PPSV 23	33	MSD	Valid	risk		08/03/2011	PPSV 23	33	MSD	Valid	risk		08/03/2012	PCV 13	133	PFR	Valid	Risk				
2016-UC-0179	traveler who plans to spend a month or longer in an endemic area and has experienced a severe allergic reaction after previous dose of Japanese Encephalitis vaccine.	12/10/1977	M	082	Severe allergic reaction after previous dose of Japanese Encephalitis		165	Longer-term (e.g., 1 month or more) travel to a JE-endemic area					Contraindicated	05/15/2016	Japanese Encephalitis, VC	134	VAL	Valid	risk																	
2016-UC-0180	traveler who plans to spend a month in an endemic area and has had an adverse reaction to a vaccine component of Japanese Encephalitis vaccine.	08/19/1981	F	080	Adverse reaction to vaccine component		165	Longer-term (e.g., 1 month or more) travel to a JE-endemic area					Contraindicated	11/01/2015	Japanese Encephalitis, VC	134	VAL	Valid	risk																	
2016-UC-0181	Patient is an animal handler with no previous history of the Rabies vaccination.	09/24/1976	M	061	Animal handlers								Not Complete																							
2016-UC-0182	Patient is an animal handler and has received the first dose of the Rabies risk 3 dose frequent vaccine series.	09/24/1976	M	061	Animal handlers								Not Complete	08/01/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk																	
2016-UC-0183	Patient is an animal handler and has received the second dose of the Rabies risk 3 dose frequent vaccine series.	09/24/1976	M	061	Animal handlers								Not Complete	08/01/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk		08/08/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk										
2016-UC-0184	Patient is an animal handler and has received three doses of the Rabies risk 3 dose frequent vaccine series.	09/24/1976	M	061	Animal handlers								Not Complete	08/01/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk		08/08/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk		08/22/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	Risk				
2016-UC-0185	Patient is a veterinarian staffer and has experienced a severe allergic reaction after previous dose of Rabies vaccine.	05/13/1984	F	113	Severe allergic reaction after previous dose of Rabies		060	Veterinarians and their staff					Contraindicated	07/29/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk																	
2016-UC-0186	Patient has adverse reaction to Rabies vaccine component	03/17/1986	F	080	Adverse reaction to vaccine component		060	Veterinarians and their staff					Contraindicated	01/13/2016	Rabies - IM Diploid cell culture	175	NOV	Valid	risk																	
2016-UC-0187	Patient has experienced a severe allergic reaction to egg protein.	12/15/1968	M	101	Allergic reaction to egg protein		045	Travel to country with a Yellow Fever vaccination entry requirement					Contraindicated																								
2016-UC-0188	Patient is a microbiology laboratorian who works frequently with S.Typhi Carrier and has received the Risk 4 dose vaccine series and the 5 year booster dose.	03/10/1977	F	051	Microbiology laboratorians who work frequently with S. typhi								Not Complete	07/10/2016	Typhoid capsular polysaccharide	25	PMC	Valid	risk		07/10/2021	Typhoid capsular polysaccharide	25	PMC	Valid	risk										

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2016-UC-0189	Patient is a microbiology laboratorian who has experience a severe allergic reaction after previous dose of Typhoid vaccine	10/08/1972	M	084	Severe allergic reaction after previous dose of Typhoid		051	Microbiology laboratorians who work frequently with S. typhi					Contraindicated	08/15/2016	Typhoid capsular polysaccharide	101	PMC	Valid	risk																	
2016-UC-0190	Patient is 22 years of age smokes and has asthma and has not received the Pneumococcal risk dose.	07/22/1994	M	027	Asthma		042	Smoke cigarettes					Not Complete																									
2016-UC-0191	Patient is a smoker, has asthma and has received the Pneumococcal risk 1 dose series.	07/22/1994	M	027	Asthma		042	Smoke cigarettes					Not Complete	10/13/2016	PPSV 23	33	MSD	Valid	risk																	
2016-UC-0192	Patient is a smoker, has diabetes, and asthma and has not received the Pneumococcal risk 1 dose vaccine.	08/14/1965	M	014	Diabetes		027	Asthma		042	Smoke cigarettes		Not Complete																							
2016-UC-0193	Patient is a smoker, has diabetes, and has asthma and has received the Pneumococcal risk 1 dose series.	08/14/1965	M	014	Diabetes		027	Asthma		042	Smoke cigarettes		Not Complete	07/12/2016	PPSV 23	33	MSD	Valid	risk																	
2016-UC-0194	Patient is 28 years of age, is MSM, has HIV, is an illicit drug user, and has not been vaccinated with the Hep B vaccine.	03/23/1988	M	036	Men who have sex with men		155	HIV/AIDS - not severely immunocompromised		041	Illicit injection drug use		Not Complete																									
2016-UC-0195	Patient is MSM, has HIV, and is an illicit drug user, and has received the first dose of the Hep B vaccine (Hep B Risk 3-dose series)	03/23/1988	M	036	Men who have sex with men		155	HIV/AIDS - not severely immunocompromised		041	Illicit injection drug use		Not Complete	05/19/2016	Hep B, Adult	43	MSD	Valid	risk																	
2016-UC-0196	Patient is MSM, has HIV, is an illicit drug user, and has received the second dose of the Hep B Risk 3-dose series	03/23/1988	M	036	Men who have sex with men		155	HIV/AIDS - not severely immunocompromised		041	Illicit injection drug use		Not Complete	05/19/2016	Hep B, Adult	43	MSD	Valid	risk		06/16/2016	Hep B, Adult	43	MSD	Valid	risk										
2016-UC-0197	Patient is MSM, has HIV, is an illicit drug user, and has received all three doses of the Hep B Risk 3-dose series	03/23/1988	M	036	Men who have sex with men		155	HIV/AIDS - not severely immunocompromised		041	Illicit injection drug use		Complete	05/19/2016	Hep B, Adult	43	MSD	Valid	risk		06/16/2016	Hep B, Adult	43	MSD	Valid	risk		09/19/2016	Hep B, Adult	43	MSD	Valid	Risk			
2016-UC-0198	Patient is 29 years of age, a microbiologist who is frequently exposed to Neisseria meningitidis, and who plans to travel to countries where meningococcal disease is endemic.	07/13/1977	F	050	Microbiologists routinely exposed to Neisseria meningitidis		164	Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic					Not Complete																									
2016-UC-0200	Patient is using dialysis and has had a previous severe allergic reaction to vaccine ingredient yeast (Energix B)	04/28/1949	M	097	Severe allergic reaction after previous dose of Hepatitis B		032	Dialysis patient					Contraindicated	05/17/2015	Hep B, Adult	43	SKB	Valid	risk																	
2016-UC-0201	Patient is an animal handler who has had a severe allergic reaction after previous dose of Rabies	03/21/1979	M	113	Severe allergic reaction after previous dose of Rabies		061	Animal handlers					Contraindicated	04/27/2016	Rabies - IM fibroblast culture	176	PMC	Valid	risk																	
2016-UC-0202	Patient is pregnant, and does not have evidence of immunity from Rubella	06/01/1985	F	007	Pregnant								Contraindicated																							
2016-UC-0203	Patient is seeking protection, and has had a severe allergic reaction after previous dose of Meningococcal B vaccine.	01/13/1995	M	116	Severe allergic reaction after previous dose of Meningococcal B		001	Patient seeks protection					Contraindicated	06/28/2016	meningococcal B, OMV	163		Valid	risk																	
2017-UC-0001	Patient is 9 years of age, female, with a history of sexual assault, and has received two previous doses of HPV vaccine at least 6 months apart.	07/12/2006	F	169	History of sexual abuse or assault								Complete	07/12/2015	9vHPV	165	MSD	Valid	risk		01/23/2016	9vHPV	165	MSD	Valid	risk										

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
			M	158									Not Complete																									
2017-UC-0002	Patient is 15 years of age, with a history of immunosuppressive therapy, and has not received any previous doses of the HPV vaccine.	10/01/2001			Immunosuppressive therapy																																	
2017-UC-0003	Patient is 15 years of age, with a immunosuppressive therapy and has received the first dose of the HPV vaccine 3 dose series	10/01/2001	M	158	Immunosuppressive therapy								Not Complete	01/08/2017	9vHPV	165	MSD	Valid	risk																		
2017-UC-0004	Patient is 15 years of age, with a immunosuppressive therapy and has received the first and second dose of the 3 dose HPV vaccine series.	10/01/2001	M	158	Immunosuppressive therapy								Not Complete	01/08/2017	9vHPV	165	MSD	Valid	risk		02/05/2017	9vHPV	165	MSD	Valid	risk											
2017-UC-0005	Patient is 15 years of age, with a history of immunosuppressive therapy, and has received all three recommended doses of the HPV vaccine series.	10/01/2001	M	158	Immunosuppressive therapy								Complete	01/08/2017	9vHPV	165	MSD	Valid	risk		02/05/2017	9vHPV	165	MSD	Valid	risk		06/08/2017	9vHPV	165	MSD	Valid	Risk				
2017-UC-0007	Patient is 11 years of age, with generalized malignant neoplasm, and has not received any previous does of the HPV vaccine.	06/02/2005	F	156	Generalized malignant neoplasm								Not Complete																								
2017-UC-0008	Patient is 11 years of age, with generalized malignant neoplasm and has received the first dose of the HPV 3 dose vaccine series.	06/02/2005	F	156	Generalized malignant neoplasm								Not Complete	08/01/2016	9vHPV	165	MSD	Valid	risk																		
2017-UC-0009	Patient is 11 years of age, with generalized malignant neoplasm and has received the second dose of the HPV vaccine at 4 weeks later.	06/02/2005	F	156	Generalized malignant neoplasm								Not Complete	08/01/2016	9vHPV	165	MSD	Valid	risk		08/29/2016	9vHPV	165	MSD	Valid	risk											
2017-UC-0010	Patient is 11 years of age, with generalized malignant neoplasm and has received all three doses of the HPV 3 dose vaccine series.	06/02/2005	F	156	Generalized malignant neoplasm								Complete	08/01/2016	9vHPV	165	MSD	Valid	risk		08/29/2016	9vHPV	165	MSD	Valid	risk		01/23/2017	9vHPV	165	MSD	Valid	risk				
2017-UC-0011	Patient is an adult with persistent complement component deficiencies and has not received any previous doses of the Men B vaccine	09/02/1995	M	151	Persistent complement, properdin, or factor B deficiency								Not Complete																								
2017-UC-0012	Patient is an adult with persistent complement component deficiencies and has received the first dose of the 2 dose Men B (Bexsero) vaccine	09/02/1995	M	151	Persistent complement, properdin, or factor B deficiency								Not Complete	03/02/2017	meningococcal B, OMV	163	NOV	Valid	risk																		
2017-UC-0014	Patient is 38 years of age, a microbiologist who is routinely exposed to Neisseria Meningitis, and who has received the Risk 1 dose and the 5 years booster dose for Men ACWY	07/13/1977	F	050	Microbiologists routinely exposed to Neisseria meningitidis								Not Complete	07/13/2010	Meningococcal, MCV4P	114	PMC	Valid	risk		07/13/2015	Meningococcal, MCV4P	114	PMC	Valid	risk											
2017-UC-0015	Patient is 35 years of age and is traveling to a country that has active cholera transmission.	02/17/1982	M	008	Travel to an area of active cholera transmission								Not Complete																								

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2017-UC-0016	Patient is 35 years of age and is traveling to a country that has active cholera transmission and has received the Cholera 1-dose series.	02/17/1982	M	008	Travel to an area of active cholera transmission								Complete	07/18/2017	Cholera	174	PAX	Valid	risk																	
2017-UC-0017	Patient is 28 years of age and has a severe allergic reaction after previous dose of the Cholera vaccine.	08/01/1989	M	119	Severe allergic reaction after previous dose of cholera		008	Travel to an area of active cholera transmission					Contraindicated																							
2018-UC-0001	Patient is 7 years of age with persistent complement and has received the second dose, of the Risk 3 dose Men B vaccine series, at greater than or equal to 6 months after the first administered dose.	03/10/2003	M	151	Persistent complement, properdin, or factor B deficiency								Complete	03/22/2018	meningococcal B, recombinant	162	PFR	Valid	risk		09/22/2018	meningococcal B, recombinant	162	PFR	Valid	risk										
2018-UC-0002	Patient is 7 years has persistent complement and has received the first dose of the MenACWY vaccine at 9 months, second dose at 7 years.	01/02/2011	M	151	Persistent complement, properdin, or factor B deficiency								Not Complete	10/02/2011	Meningococcal, MCV4O	136	NOV	Valid	risk		01/02/2018	Meningococcal, MCV4O	136	NOV	Valid	risk										
2018-UC-0004	Patient is 21 years of age with Hepatitis C Infection and has not received a dose of the Hep B vaccine.	06/23/1997	F	005	Hepatitis C virus infection								Not Complete																							
2018-UC-0005	Patient is 21 years of age with Hepatitis C Infection and has received the first dose in the Risk 2 (Heplisav) dose Hep B vaccine.	06/23/1997	F	005	Hepatitis C virus infection								Not Complete	06/27/2018	HepB-CpG	189	DVX	Valid	risk																	
2018-UC-0006	Patient is 21 years of age with Hepatitis C Infection and has received the second dose in the Risk 2 dose Hep B vaccine.	06/23/1997	F	005	Hepatitis C virus infection								Complete	06/27/2018	HepB-CpG	189	DVX	Valid	risk		07/25/2018	HepB-CpG	189	DVX	Valid	risk										
2019-UC-0001	Patient is 21 years of age and traveling to an endemic area during JE Transmission, and has received the two primary doses and the booster dose.	09/10/1983	M	165	Longer-term (e.g., 1 month or more) travel to a JE-endemic area								Complete	04/28/2016	Japanese Encephalitis, VC	134	VAL	Valid	risk		05/25/2016	Japanese Encephalitis, VC	134	VAL	Valid	risk		07/19/2019	Japanese Encephalitis, VC	134	VAL	Valid	risk			
2019-UC-0002	Patient is 21 years of age with chronic renal failure and no standard dose of PCV vaccine	04/29/2017	F	066	Chronic renal failure								Not Complete	07/01/2019	PCV 13	133		Valid	risk																	
2019-UC-0003	Patient is 21 years of age with chronic renal failure and has received the first dose of the PCV Vaccine.	04/29/2017	F	066	Chronic renal failure								Not Complete																							
2019-UC-0008	Patient is 65 years with Cochlear implants and no doses of PCV 13 or PPSV23.	08/06/1954	M	011	Cochlear implants								Not Complete																							
2019-UC-0009	Patient is 65 years with Cochlear implants with PCV13 dose but no PPSV.	08/06/1954	M	011	Cochlear implants								Not Complete	08/06/2019	PCV 13	133	PFR	Valid	risk																	
2019-UC-0010	Patient is 65 years with Cochlear implants and has received PCV and PPSV dose	08/06/1954	M	011									Complete	08/06/2019	PCV 13	133	PFR	Valid	risk		08/06/2020	PPSV 23	33	PFR	Valid	risk										
2019-UC-0011	Patient is an adult with no history of the Hep B vaccine and is seek protection.	08/15/1971	F	001	Patient seeks protection								Not Complete						risk																	
2019-UC-0012	Patient is an adult with the first dose of the Hep B (Heplisav) vaccine.	08/15/1971	F	001	Patient seeks protection								Not Complete	09/06/2019	HepB-CpG	189	DVX	Valid	risk																	
2019-UC-0013	Patient is an adult with two doses (Dose #1 is Heplisav vaccine) of the Hep B vaccine.	08/15/1971	F	001	Patient seeks protection								Not Complete	09/06/2019	HepB-CpG	189	DVX	Valid	risk		10/04/2019	Hep B	43		Valid	risk										

CDC_Test_ID	Test_Case_Name	DOB	Gender	Observation_Code_1	Observation_Text_1	Observation_Date_1	Observation_Code_2	Observation_Text_2	Observation_Date_2	Observation_Code_3	Observation_Text_3	Observation_Date_3	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Series_Type_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Series_Type_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Series_Type_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4
2019-UC-0014	Patient is an adult with three doses of the Hep B vaccine.	08/15/1971	F	001	Patient seeks protection								Not Complete	09/06/2019	Hep B	189	DVX	Valid	risk		10/04/2019	Hep B	43	MSD	Valid	risk		11/01/2019	Hep B	43	MSD	Valid	risk				
2019-UC-0015	Patient is an adult with four doses (first and fourth doses are Heplisav) of the Hep B vaccine	08/15/1971	F	001	Patient seeks protection								Complete	09/06/2019	HepB-CpG	189	DVX	Valid	risk		10/04/2019	Hep B	43	MSD	Valid	risk		11/01/2019	Hep B	43	MSD	Valid	risk		11/29/2019	HepB-CpG	189

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2015-UC-0012																										2	06/25/2015	06/25/2015	07/22/2015		Var	05/28/2015	Vaccine: Off Label	09/22/2017	12/09/2019	Recommended based on interval	updated test case title and description	4.1
2016-UC-0002																										-					DTaP	12/10/2010	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0003																										2	04/30/2011	06/02/2011	07/29/2011		DTaP	04/02/2011	All Valid: Forecast Test	01/01/2013	03/21/2019	Recommended based on age		4.0
2016-UC-0004																										-					DTaP	12/15/2010	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0005																										-					DTaP	08/02/2010	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0006																										-					Flu	10/08/2014	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0007																										-					HepA	03/04/2009	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0008																										-					HepB	11/11/2006	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0009																										-					Hib	08/02/2010	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0010																										-					HPV	06/19/2011	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0011																										-					Meningococcal	03/15/2011	All Valid: Forecast Test	01/01/2013	03/21/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0012																										-					MMR	09/02/2011	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Updated Observation code to 154 and added description	4.0
2016-UC-0013																										-					MMR	09/10/2011	No Doses Administered	01/01/2013	03/22/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0014																										-					Pneumococcal	09/11/2007	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0015																										-					POL	09/24/2011	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Updated assessment date	4.0
2016-UC-0016																										-					Rota	03/14/2012	No Doses Administered	01/01/2013	07/29/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0017																										-					Rota	04/01/2012	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0018																										-					Rota	05/01/2012	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0019																										-					Var	04/01/2005	No Doses Administered	01/01/2013	03/22/2019	Not recommended: immune	Updated assessment date	4.0
2016-UC-0020																										-					Var	06/01/2006	No Doses Administered	01/01/2013	07/29/2019	Not recommended: immune	Added description	4.0
2016-UC-0021																										-					Var	03/15/2012	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Updated observation code to 154 and added description	4.0
2016-UC-0022																										-					Var	12/20/2010	All Valid: Forecast Test	01/01/2013	03/22/2019	Not recommended: contraindication	Updated assessment date	4.0
2016-UC-0023																										-					Var	11/18/2011	No Doses Administered	01/01/2013	07/29/2019	Not recommended: immune	Updated assessment date	4.0
2016-UC-0024																										-					Var	06/16/1991	No Doses Administered	06/23/2015	07/29/2019	Not recommended: immune	Updated assessment date	4.0
2016-UC-0025																										-					Var	06/16/2004	No Doses Administered	06/23/2015	07/29/2019	Not recommended: immune		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0026																										-					Var	06/19/2015	No Doses Administered	06/23/2015	07/29/2019	Not recommended: immune	Updated assessment date	4.0
2016-UC-0027																										2	06/25/2015	06/25/2015	07/22/2015		Var	05/28/2015	All Valid: Forecast Test	06/23/2015	03/22/2019	Recommended based on interval	Added description and Updated past due date	4.0
2016-UC-0028																										-					Var	07/31/2012	All Valid: Forecast Test	06/23/2015	07/29/2019	Recommended based on interval	Updated assessment date	4.0
2016-UC-0029																										-					Var	06/19/2015	No Doses Administered	06/23/2015	07/29/2019	Not recommended: contraindication	Updated assessment date	4.0
2016-UC-0031																										1	06/16/2005	06/16/2005		Updated to reflect that RZV can be used instead of ZVL. The use of the new product removes the test cases from being Contraindicated.	Zoster	06/16/2015	No Doses Administered	06/23/2015	03/22/2019	Recommended based on Condition	Added description	4.0
2016-UC-0032																										2	05/28/2015	05/28/2015	05/27/2021	V4.1 added past due date v 4.0 Updated to reflect that if a patient is a healthcare worker and has received one dose of the MMR vaccine that a second dose should be administered 4 weeks later.	MMR	04/30/2015	All Valid: Forecast Test	06/23/2015	12/05/2019	Recommended based on interval	Updated to display accurate forecasting dates, assessment date, and added description	4.1
2016-UC-0033																										1	04/01/1986	04/01/1986	04/28/1987		HepA	04/23/2016	No Doses Administered	08/01/2016	07/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0034																										2	01/01/2017	01/01/2017			HepA	07/01/2016	All Valid: Forecast Test	08/01/2016	03/23/2019	Recommended based on Condition	Added description	4.0
2016-UC-0035																										-					HepA	11/01/2016	All Valid: Forecast Test	08/01/2016	03/23/2019	Recommended based on Condition	Updated Past Due date, assessment date, and added description	4.0
2016-UC-0036																										1	04/12/1962	04/12/1962	05/09/1963		HepA	08/01/2016	No Doses Administered	08/01/2016	07/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0037																										2	08/29/2016	08/29/2016			HepA	08/01/2016	All Valid: Forecast Test	08/01/2016	03/23/2019	Recommended based on Condition	Updated to reflect the recommended interval of 5 months for dose #3. and added description	4.0
2016-UC-0038																										3	10/01/2016	10/01/2016			HepA	04/29/2016	All Valid: Forecast Test	08/01/2016	05/22/2019	Recommended based on Condition	Added description	4.0
2016-UC-0039																										-					HepA	02/04/2017	All Valid: Forecast Test	08/01/2016	05/22/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0040																										1	01/12/2009	01/12/2009			HepB	03/12/2016	No Doses Administered	08/09/2016	07/29/2019	Recommended based on Condition	Updated assessment date, and Added description	4.0
2016-UC-0042																										3	06/07/2016	06/07/2016	06/15/2016		HepB	05/24/2016	All Valid: Forecast Test	08/09/2016	05/22/2019	Recommended based on Condition	Updated CVX code to 104 to reflect Twinrix vaccine. Updated observation code to nn1	4.1
2016-UC-0043																										4	05/17/2017	05/17/2017			HepB	06/07/2016	All Valid: Forecast Test	08/09/2016	05/22/2019	Recommended based on Condition	Updated to reflect that the fourth dose of the Risk 4 dose Twinrix series should be forecasted 12 months after the first dose.	4.0
2016-UC-0044	SKB	Valid	risk																							-					HepB	06/17/2017	All Valid: Forecast Test	08/09/2016	07/29/2019	Recommended based on Condition	Added description and updated assessment date	4.0
2016-UC-0045																										1	01/17/1985	01/17/1985			HepB	04/22/2016	No Doses Administered	08/22/2016	07/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0046																										2	05/20/2016	05/20/2016			HepB	04/22/2016	All Valid: Forecast Test	08/22/2016	05/22/2019	Recommended based on Condition	Added description	4.0
2016-UC-0047																										3	10/20/2016	10/20/2016			HepB	05/20/2016	All Valid: Forecast Test	08/22/2016	05/22/2019	Recommended based on Condition	Added description	4.0
2016-UC-0048																										-					HepB	11/12/2016	All Valid: Forecast Test	08/22/2016	05/22/2019	Recommended based on Condition	Updated forecast date to reflect minimum age for dose 1, updated assessment date	4.0
2016-UC-0049																										1	02/13/1966	02/13/1966			HepB	03/13/2016	No Doses Administered	08/26/2016	07/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0050																										2	04/10/2016	04/10/2016			HepB	03/13/2016	All Valid: Forecast Test	08/26/2016	05/22/2019	Recommended based on Condition	Added description	4.0
2016-UC-0051																										3	05/08/2016	05/08/2016			HepB	04/10/2016	All Valid: Forecast Test	08/26/2016	05/22/2019	Recommended based on Condition	Updated forecast date to reflect accurate dose four forecast. Added description	4.0
2016-UC-0052																										4	09/08/2016	09/08/2016			HepB	05/08/2016	All Valid: Forecast Test	08/26/2016	04/08/2019	Recommended based on Condition	Updated to add a valid fourth dose administration. Updated assessment date	4.0
2016-UC-0053	SKB	Valid	risk																							-					HepB	09/08/2016	All Valid: Forecast Test	08/26/2016	07/29/2019	Recommended based on Condition	Added description, updated assessment date	4.0
2016-UC-0054																										1	07/15/2015	07/15/2015			Hib	07/15/2015	No Doses Administered	08/11/2016	07/29/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0055																										2	10/10/2016	10/10/2016			Hib	08/15/2016	All Valid: Forecast Test	08/11/2016	07/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0056																										-					Hib	10/03/2016	All Valid: Forecast Test	08/11/2016	01/07/2019	Recommended based on Condition	Added description, updated assessment date	4.0
2016-UC-0057																										2	08/10/2015	08/10/2015			Hib	01/10/2015	All Valid: Forecast Test	08/25/2016	07/29/2019	Recommended based on Condition	Updated to display accurate forecasting date based on ACIP recommendations, added description	4.0
2016-UC-0058																										3	06/08/2016	06/08/2016			Hib	04/13/2016	All Valid: Forecast Test	08/25/2016	05/04/2019	Recommended based on Condition	Added description	4.0
2016-UC-0059																										-					Hib	06/08/2016	All Valid: Forecast Test	08/25/2016	04/25/2019	Recommended based on Condition	Updated to display accurate forecasting date based on ACIP recommendations	4.0
2016-UC-0060																										3	09/02/2013	09/02/2013			Hib	07/08/2013	All Valid: Forecast Test	08/11/2016	01/07/2019	Recommended based on Condition	Added description	4.0
2016-UC-0061																										-				Vaccination 14 or more days before splenectomy is suggested.	Hib	05/14/2016	All Valid: Forecast Test	08/11/2016	04/25/2019	Recommended based on Condition	Updated earliest and recommended forecast dates to age 15 mos based on childhood recommendations for undergoing elective splenectomy and added description.	4.0
2016-UC-0062																										1	09/22/2010	09/22/2010		Vaccination 14 or more days before splenectomy is suggested.	Hib	07/01/2016	No Doses Administered	08/15/2016	12/02/2019	Recommended based on Condition	Added description	4.1
2016-UC-0063																										-				Vaccination 14 or more days before splenectomy is suggested.	Hib	07/01/2016	All Valid: Forecast Test	08/15/2016	01/07/2019	Recommended based on Condition	Updated Earliest and Recommended date to reflect 15 mos,	4.0
2016-UC-0064																										1	10/10/1998	10/10/1998			Hib	08/03/2016	No Doses Administered	08/15/2016	12/02/2019	Recommended based on Condition	Added description, updated assessment	4.1

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
																													Vaccination 14 or more days before splenectomy is suggested.								
2016-UC-0065																										-					Hib	08/03/2016	All Valid: Forecast Test	08/15/2016	01/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0066																										1	07/23/2004	07/23/2004			Hib	02/03/2016	No Doses Administered	08/23/2016	01/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0067																										-				At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	02/03/2016	No Doses Administered	08/23/2016	01/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0068																										1	09/25/2010	09/25/2010		At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	09/19/2014	No Doses Administered	08/15/2016	01/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0069																										2	10/17/2014	10/17/2014		At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	09/19/2014	All Valid: Forecast Test	08/15/2016	01/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0070																										3	11/14/2014	11/14/2014		At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	10/17/2014	All Valid: Forecast Test	08/15/2016	01/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0071																										-				At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	07/27/2014	All Valid: Forecast Test	08/15/2016	01/08/2019	Recommended based on Condition	Added Vaccine Group, Descriptions, and forecast date	4.0
2016-UC-0072																										1	06/24/1996	06/24/1996		At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	07/27/2016	No Doses Administered	08/22/2016	01/09/2019	Recommended based on Condition	Added description	4.0
2016-UC-0073																										2	08/22/2016	08/22/2016		At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	07/25/2016	All Valid: Forecast Test	08/22/2016	01/09/2019	Recommended based on Condition	Added description	4.0
2016-UC-0074																										3	09/19/2016	09/19/2016		At least 4 weeks should separate doses, 6 to 12 months after a successful transplant.	Hib	08/22/2016	All Valid: Forecast Test	08/25/2016	01/09/2019	Recommended based on Condition	Added description	4.0
2016-UC-0075																										-					Hib	09/19/2016	All Valid: Forecast Test	08/25/2016	01/09/2019	Recommended based on Condition	added Past Due date, and description	4.0
2016-UC-0076																										1	04/04/2016	04/04/2016	04/03/2018		HPV	01/09/2017	No Doses Administered	08/15/2016	05/22/2019	Recommended based on Condition	added description	4.0
2016-UC-0077																										2	05/15/2017	06/15/2017	02/11/2018		HPV	12/15/2016	All Valid: Forecast Test	08/15/2016	05/22/2019	Recommended based on Condition	added description	4.0
2016-UC-0078																										-					HPV	01/05/2017	All Valid: Forecast Test	08/16/2016	05/04/2019	Not Recommended: Patient Complete		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0079																										-				HPV	06/01/2017	All Valid: Forecast Test	08/16/2016	01/09/2019	Recommended based on Condition	New HPV 2 dose recommendation, added description	4.0
2016-UC-0080																										1	02/15/2016	02/15/2016	02/14/2018		HPV	11/17/2016	No Doses Administered	08/16/2016	06/12/2019	Recommended based on Condition	Update test case with observational code 148. Added description	4.0
2016-UC-0083																										-				HPV	11/01/2016	All Valid: Forecast Test	08/17/2016	01/09/2019	Recommended based on Condition	added description	4.0
2016-UC-0084																										3	09/21/2016	10/21/2016	06/17/2017		HPV	05/19/2016	All Valid: Forecast Test	08/17/2016	05/04/2019	Recommended based on Condition	Updated Earliest, Recommended, and Past due dates, added description	4.0
2016-UC-0085																										1	02/02/2003	02/02/2005	03/01/2007		HPV	02/02/2016	All Valid: Forecast Test	08/17/2016	01/09/2019	Recommended based on Condition	Updated Earliest, Recommended, Past due dates, and added description	4.0
2016-UC-0086																										2	08/18/2016	08/18/2016	11/09/2016		HPV	07/21/2016	All Valid: Forecast Test	08/17/2016	01/09/2019	Recommended based on Condition	Updated Earliest, Recommended, and past due date based on HPV Recommendations, added description	4.0
2016-UC-0087																										3	09/03/2014	10/03/2014	11/30/2014		HPV	05/01/2014	All Valid: Forecast Test	08/18/2016	01/09/2019	Recommended based on Condition	Added description	4.0
2016-UC-0088																										-				HPV	09/14/2015	All Valid: Forecast Test	08/18/2016	01/09/2019	Recommended based on Condition	Added description	4.0
2016-UC-0089																										1	09/01/1984	09/01/1984		ACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously, a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended, can be considered, or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available. This includes long-term travelers ≥1 month, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week	Japanese Encephalitis	08/15/2016	No Doses Administered	08/23/2016	05/04/2019	Recommended based on Condition	Updated earliest and recommended dates to 7 days. Added description	4.0
2016-UC-0090																										2	08/22/2016	08/22/2016	09/11/2016	ACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously, a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended, can be considered, or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available. This includes long-term travelers ≥1 month, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week	Japanese Encephalitis	08/15/2016	All Valid: Forecast Test	08/23/2016	12/02/2019	Recommended based on Condition		4.1

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0091																										3	05/25/2017	05/25/2017		ACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously, a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended, can be considered, or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available. This includes long-term travelers ≥1 month, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week	Japanese Encephalitis	07/10/2019	All Valid: Forecast Test	08/23/2016	07/19/2019	Recommended based on Condition	added description.	4.0
2016-UC-0092																										1	08/28/2016	08/28/2016	02/27/2017	Children who received MMR vaccine before age 12 months should be considered potentially susceptible to all three diseases and should be revaccinated with 2 doses of MMR vaccine, the first dose administered when the child is aged 12 through 15 months (12 months if the child remains in an area where disease risk is high) and the second dose at least 28 days later.	MMR	08/28/2016	No Doses Administered	08/28/2016	04/25/2019	Recommended based on Condition	added description	4.0
2016-UC-0093																										2	02/28/2017	02/28/2017	07/25/2017		MMR	08/28/2016	All Valid: Forecast Test	08/18/2016	04/25/2019	Recommended based on Condition	added description	4.0
2016-UC-0094																										3	12/12/2016	12/12/2016			MMR	06/12/2016	All Valid: Forecast Test	08/18/2016	03/28/2019	Recommended based on Condition	Updated title and description of test case.	4.0
2016-UC-0095																										4	07/10/2016	07/10/2016			MMR	12/12/2016	All Valid: Forecast Test	08/18/2016	10/30/2019	Recommended based on Condition	Updated title and description of test case.	4.1
2016-UC-0096	MSD	Valid	risk																							-					MMR	01/12/2017	All Valid: Forecast Test	08/18/2016	10/30/2019	Recommended based on Condition	added description	4.1
2016-UC-0097																										1	07/04/2008	07/04/2008			MenB	07/04/2016	No Doses Administered	07/04/2016	04/25/2019	Recommended based on Condition	added description	4.0
2016-UC-0098																										2	08/01/2016	08/01/2016			MenB	07/04/2016	All Valid: Forecast Test	08/18/2016	03/07/2019	Recommended based on Condition	added description	4.0
2016-UC-0099																										-					MenB	01/04/2017	All Valid: Forecast Test	01/04/2017	03/07/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0100																										1	03/28/2016	03/28/2016			MenB	03/28/2016	No Doses Administered	08/30/2016	01/10/2019	Recommended based on Condition	Added description	4.0
2016-UC-0101																										2	04/25/2016	04/25/2016			MenB	03/28/2016	All Valid: Forecast Test	08/30/2016	01/10/2019	Recommended based on Condition	Added description	4.0
2016-UC-0103																										1	10/01/1986	10/01/1986			MenB	06/23/2016	No Doses Administered	09/07/2016	01/10/2019	Recommended based on Condition	Added past due date.	4.0
2016-UC-0104																										2	07/21/2016	07/21/2016	08/17/2016		MenB	06/23/2016	All Valid: Forecast Test	09/07/2016	12/02/2019	Recommended based on Condition	Updated based on change in version 3.4. Dose 2 can be administered at 4 weeks - 4 days, 4 weeks, added description.	4.1
2016-UC-0105																										3	12/23/2016	12/23/2016		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	MenB	07/21/2016	All Valid: Forecast Test	09/07/2016	12/02/2019	Recommended based on Condition	Updated Earliest and Recommended dates, added description	4.1
2016-UC-0107																										1	04/14/2015	04/14/2015		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	04/14/2015	No Doses Administered	09/07/2016	01/10/2019	Recommended based on Condition	Added description	4.0
2016-UC-0108																										2	06/09/2015	06/09/2015		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	04/14/2015	All Valid: Forecast Test	09/07/2016	01/11/2019	Recommended based on Condition	Added description	4.0
2016-UC-0109																										3	08/04/2015	08/04/2015		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	06/09/2015	All Valid: Forecast Test	09/07/2016	01/14/2019	Recommended based on Condition	Added description	4.0
2016-UC-0110																										4	02/04/2016	02/04/2016		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	08/04/2015	All Valid: Forecast Test	09/08/2016	01/14/2019	Recommended based on Condition	Added description	4.0
2016-UC-0111	NOV	Valid	risk																							5	02/14/2019	02/14/2019		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	02/14/2016	All Valid: Forecast Test	09/08/2016	01/14/2019	Recommended based on Condition	Added description	4.0
2016-UC-0112	NOV	Valid	risk		########	Meningococcal, MCV4O	136	NOV	Valid	risk																6	08/23/2021	08/23/2021		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	08/23/2016	All Valid: Forecast Test	09/08/2016	01/14/2019	Recommended based on Condition	Added Description	4.0
2016-UC-0113	NOV	Valid	risk		########	Meningococcal, MCV4O	136	NOV	Valid	risk		01/01/2016	Meningococcal, MCV4O	136	NOV	Valid	risk										7	01/01/2021	01/01/2021			Meningococcal	01/01/2016	All Valid: Forecast Test	09/08/2016	01/14/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change Added Description	Changed_In_Version
2016-UC-0114																										1	12/10/2015	12/10/2015		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	12/10/2015	No Doses Administered	09/08/2016	01/14/2019	Recommended based on Condition	Added description	4.0
2016-UC-0115																										2	03/03/2016	03/03/2016		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	12/10/2015	All Valid: Forecast Test	09/09/2016	01/14/2019	Recommended based on Condition	added description	4.0
2016-UC-0116																										3	05/10/2019	05/10/2019		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	05/10/2016	All Valid: Forecast Test	09/09/2016	01/10/2019	Recommended based on Condition	Updated Assessment Date. Added description	4.0
2016-UC-0117																										1	09/28/2015	09/28/2015		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	09/30/2015	No Doses Administered	09/09/2016	12/02/2019	Recommended based on Condition	Added description	4.1
2016-UC-0123																										1	04/18/1994	04/18/1994		If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	05/02/2016	All Valid: Forecast Test	09/09/2016	01/15/2019	Recommended based on Condition	added description	4.0
2016-UC-0124																										2	06/27/2016	06/27/2016	07/24/2016	If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.	Meningococcal	05/02/2016	All Valid: Forecast Test	09/09/2016	03/07/2019	Recommended based on Condition	Added description	4.0
2016-UC-0125																										3	06/27/2021	06/27/2021			Meningococcal	06/27/2016	All Valid: Forecast Test	09/09/2016	03/07/2019	Recommended based on Condition	added description	4.0
2016-UC-0127																										-				Meningococcal vaccines that are licensed for use in person aged ≥56 year are not currently available in the United States Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease should receive MenACWY conjugate vaccine	Meningococcal	01/17/2016	All Valid: Forecast Test	08/30/2016	03/07/2019	Recommended based on Condition	, added description	4.0
2016-UC-0128																										1	03/07/1958	03/07/1958		Meningococcal vaccines that are licensed for use in person aged ≥56 year are not currently available in the United States Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease should receive MenACWY conjugate vaccine	Meningococcal	08/30/2016	No Doses Administered	08/30/2016	03/22/2019	Recommended based on Condition	added description.	4.0
2016-UC-0129																										2	05/23/2021	05/23/2021		Administer during each pregnancy (preferably during 27 to 36 weeks' gestation) regardless of interval since prior Td or Tdap vaccination.	Meningococcal	05/23/2016	All Valid: Forecast Test	08/30/2016	03/22/2019	Recommended based on Condition	added description	4.0
2016-UC-0130																										1		02/27/2016	05/01/2017	Administer during each pregnancy (preferably during 27 to 36 weeks' gestation) regardless of interval since prior Td or Tdap vaccination.	Tdap	08/22/2016	No Doses Administered	08/23/2016	03/28/2019	Recommended based on Condition	added description	4.0
2016-UC-0131																										-					Tdap	03/01/2017	All Valid: Forecast Test	08/23/2016	03/28/2019	Recommended based on Condition	Added description and Updated past due date	4.0
2016-UC-0132	PMC	Valid	standard																							5	11/23/1995	11/23/1995	11/23/1995		IPOL	04/04/2016	All Valid: Forecast Test	08/19/2016	01/15/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0133	PMC	Valid	standard		########	IPV	10	PMC	Valid	standard																-					IPOL	04/04/2016	All Valid: Forecast Test	08/19/2016	01/15/2019	Recommended based on Condition	Updated test case description and first dose administration to match more closely to the recommendations for adults at risk for polio and added description. Added description	4.0
2016-UC-0134																										1	08/10/1979	08/10/1979			IPOL	09/05/2016	No Doses Administered	09/05/2016	01/15/2019	Recommended based on Condition	Added Past Due date, added description	4.0
2016-UC-0135																										2	10/03/2016	10/03/2016	10/30/2016		IPOL	09/05/2016	All Valid: Forecast Test	08/19/2016	01/15/2019	Recommended based on Condition	Added Past Due date, added description	4.0
2016-UC-0136																										3	04/03/2017	04/03/2017	10/02/2017		IPOL	10/03/2016	All Valid: Forecast Test	08/19/2016	01/15/2019	Recommended based on Condition	Added description	4.0
2016-UC-0137																										-					IPOL	04/03/2017	All Valid: Forecast Test	08/19/2016	01/15/2019	Recommended based on Condition	Added description	4.0
2016-UC-0138																										4	01/19/2016	01/19/2016		The 6 month booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.	Rabies	07/19/2015	All Valid: Forecast Test	08/26/2016	01/15/2019	Recommended based on Condition	Updated forecast date to reflect dose #5 at 6 months, added description.	4.0
2016-UC-0139	NOV	Valid	risk																							5	07/19/2016	07/19/2016		The 6 month booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.	Rabies	01/19/2016	All Valid: Forecast Test	08/26/2016	01/16/2019	Recommended based on Condition	Updated forecast dates to reflect an indication begin age of 18 for the risk, added description	4.0
2016-UC-0140																										1	09/21/1986	09/21/1986			Rabies	05/16/2016	No Doses Administered	08/26/2016	01/16/2019	Recommended based on Condition	added CVX code 175, added description	4.0
2016-UC-0141																										2	05/23/2016	05/23/2016			Rabies	05/16/2016	All Valid: Forecast Test	08/26/2016	01/16/2019	Recommended based on Condition	Updated Past Due date, added description	4.0
2016-UC-0142																										3	06/06/2016	06/06/2016	06/12/2016		Rabies	05/23/2016	All Valid: Forecast Test	08/26/2016	01/16/2019	Recommended based on Condition	Updated test case to forecast a fourth dose at 6 months, added description.	4.0
2016-UC-0143																										4	12/06/2016	12/06/2016		The 2 year booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.	Rabies	06/06/2016	All Valid: Forecast Test	08/29/2016	01/16/2019	Recommended based on Condition	added description	4.0
2016-UC-0144																										4	07/09/2017	07/09/2017			Rabies	07/09/2015	All Valid: Forecast Test	08/29/2016	01/16/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
																													The 2 year booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.							added description	
2016-UC-0145	PMC	Valid	risk																							5	07/19/2019	07/19/2019			Rabies	07/19/2017	All Valid: Forecast Test	08/29/2016	03/07/2019	Recommended based on Condition	added description	4.0
2016-UC-0146																										1	04/19/1972	04/19/1972		This vaccine should be given at least 2 weeks before potential exposure. Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week	Typhoid	07/22/2016	No Doses Administered	08/19/2016	03/07/2019	Recommended based on Condition	Added description	4.0
2016-UC-0147																										2	07/22/2018	07/22/2018		This vaccine should be given at least 2 weeks before potential exposure. Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week	Typhoid	07/22/2016	All Valid: Forecast Test	08/19/2016	01/16/2019	Recommended based on Condition	Added description	4.0
2016-UC-0148																										3	07/22/2020	07/22/2020		This vaccine should be given at least 2 weeks before potential exposure. Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week	Typhoid	07/22/2018	All Valid: Forecast Test	08/19/2016	01/16/2019	Recommended based on Condition	Updated test case to forecast dose number 1 at age 6 years of age, added description	4.0
2016-UC-0149																										1	10/15/1982	10/15/1982		This vaccine should be given at least 2 weeks before potential exposure. Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week	Typhoid	08/16/2016	No Doses Administered	08/29/2016	05/02/2019	Recommended based on Condition	Updated the CVX code to 25, added description	4.0
2016-UC-0150																										2	08/16/2021	08/16/2021		A single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers but additional doses of yellow fever vaccine are recommended for certain travelers with ongoing risk. Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose of yellow fever vaccine Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated. A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel. Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection.	Typhoid	08/16/2016	All Valid: Forecast Test	08/29/2016	01/16/2019	Recommended based on Condition	added description	4.0
2016-UC-0151																										1	04/01/1965	04/01/1965		A single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers but additional doses of yellow fever vaccine are recommended for certain travelers with ongoing risk. Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose of yellow fever vaccine Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated. A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel. Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection.	Yellow Fever	09/01/2016	No Doses Administered	08/22/2016	01/16/2019	Recommended based on Condition	Added description	4.0
2016-UC-0152																										-					Yellow Fever	09/01/2016	All Valid: Forecast Test	08/22/2016	01/16/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0153																										2	07/03/2013	07/03/2013		When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.	Pneumococcal	02/12/2016	All Valid: Forecast Test	08/30/2016	01/17/2019	Recommended based on Condition	Updated to reflect the correct forecasting date, added description	4.0
2016-UC-0154																										3	04/08/2016	04/08/2016		When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.	Pneumococcal	02/12/2016	All Valid: Forecast Test	08/30/2016	01/17/2019	Recommended based on Condition	Added description	4.0
2016-UC-0155																										4	06/03/2016	06/03/2016		When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.	Pneumococcal	04/08/2016	All Valid: Forecast Test	08/30/2016	01/17/2019	Recommended based on Condition	Added description	4.0
2016-UC-0156	PFR or WAL	Valid	Risk																							5	05/17/2077	05/17/2077			Pneumococcal	05/21/2016	All Valid: Forecast Test	08/31/2016	01/17/2019	Recommended based on Condition	Updated to add Past Due date, added description	4.0
2016-UC-0157																										1	03/08/2003	03/08/2003	03/07/2062		Pneumococcal	04/16/2016	No Doses Administered	08/30/2016	01/17/2019	Recommended based on Condition	added description	4.0
2016-UC-0158																										2	03/08/2062	03/08/2062			Pneumococcal	04/16/2016	All Valid: Forecast Test	08/30/2016	01/17/2019	Recommended based on Condition	added description	4.0
2016-UC-0159																										1	09/14/2014	09/14/2014			Pneumococcal	09/14/2016	No Doses Administered	09/01/2016	01/17/2019	Recommended based on Condition	Added description	4.0
2016-UC-0160																										2	11/09/2016	11/09/2016			Pneumococcal	09/14/2016	All Valid: Forecast Test	09/01/2016	01/17/2019	Recommended based on Condition	Added description	4.0
2016-UC-0161																										3	09/14/2073	09/14/2073			Pneumococcal	11/09/2016	All Valid: Forecast Test	09/01/2016	01/17/2019	Recommended based on Condition	Added description	4.0
2016-UC-0162																										2	06/27/2016	06/27/2016			Pneumococcal	05/02/2016	All Valid: Forecast Test	09/01/2016	01/17/2019	Recommended based on Condition	added description	4.0
2016-UC-0163																										3	03/16/2066	03/16/2066			Pneumococcal	06/27/2016	All Valid: Forecast Test	09/01/2016	01/17/2019	Recommended based on Condition	Update to reflect the correct forecasting date, added description	4.0
2016-UC-0164																										2	08/01/2017	08/01/2017		When cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.	Pneumococcal	08/01/2016	All Valid: Forecast Test	09/02/2016	01/14/2019	Recommended based on Condition	Updated forecast vaccine type, added description	4.0
2016-UC-0165																										3	05/01/2042	05/01/2042			Pneumococcal	08/01/2017	All Valid: Forecast Test	09/02/2016	01/17/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
																													When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.									Updated age of patient in 4 dose. Added description	
2016-UC-0166	PFR	Valid	standard																							5	07/16/2012	07/16/2012		When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.	Pneumococcal	05/21/2012	All Valid: Forecast Test	09/02/2016	05/08/2019	Recommended based on Condition	Added description	4.0
2016-UC-0167	PFR	Valid	standard		########	PPSV 23	33	MSD	Valid	Risk																6	05/28/2021	05/28/2021		When elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.	Pneumococcal	05/28/2016	All Valid: Forecast Test	09/02/2016	01/17/2019	Recommended based on Condition	Add description	4.0
2016-UC-0168	PFR	Valid	standard		########	PPSV 23	33	MSD	Valid	Risk		05/28/2021	PPSV 23	33		Valid	Risk									7	03/21/2075	03/21/2075			Pneumococcal	05/28/2021	All Valid: Forecast Test	09/02/2016	01/17/2019	Recommended based on Condition	Added description	4.0
2016-UC-0169																										2	07/27/2016	07/27/2016			Pneumococcal	06/01/2016	All Valid: Forecast Test	09/02/2016	01/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0170																										3	06/01/2021	06/01/2021			Pneumococcal	07/27/2016	All Valid: Forecast Test	09/02/2016	01/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0171																										4	04/13/2072	04/13/2072			Pneumococcal	06/01/2021	All Valid: Forecast Test	09/02/2016	01/29/2019	Recommended based on Condition	Updated earliest and recommended forecast dates to 1 years per ACIP Guidelines, added description	4.0
2016-UC-0172																										2	08/21/2017	08/21/2017			Pneumococcal	08/21/2016	All Valid: Forecast Test	09/02/2016	01/29/2019	Recommended based on Condition	Updated earliest and recommended forecast date to 5 years after most previous dose of PPSV23, added description	4.1
2016-UC-0173																										3	08/21/2021	08/21/2021			Pneumococcal	08/21/2017	All Valid: Forecast Test	09/02/2016	12/02/2019	Recommended based on Condition	Added description	4.1
2016-UC-0174																										4	06/13/2059	06/13/2059	06/13/2059		Pneumococcal	08/21/2022	All Valid: Forecast Test	09/02/2016	01/29/2019	Recommended based on Condition	Added description	4.0
2016-UC-0175																										3	06/11/2016	06/11/2016			Pneumococcal	04/16/2016	All Valid: Forecast Test	09/06/2016	01/29/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0176																										4	04/04/2067	04/04/2067			Pneumococcal	06/11/2016	All Valid: Forecast Test	09/06/2016	12/02/2019	Recommended based on Condition	Removed the past due date Added description	4.1
2016-UC-0177																										3	08/03/2012	08/03/2012			Pneumococcal	08/03/2011	All Valid: Forecast Test	09/06/2016	01/29/2019	Recommended based on Condition	Added Past Due date, added description	4.0
2016-UC-0178																										4	07/02/2051	07/02/2051	07/02/2051		Pneumococcal	08/03/2012	All Valid: Forecast Test	09/06/2016	01/29/2019	Recommended based on Condition	Updated to reflect an additional contraindication/observation.	4.0
2016-UC-0179																										-					Japanese Encephalitis	05/15/2016	All Valid: Forecast Test	08/23/2016	01/29/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0180																										-					Japanese Encephalitis	11/01/2015	All Valid: Forecast Test	08/23/2016	01/29/2019	Not recommended: contraindication	Added description	4.0
2016-UC-0181																										1	09/24/1976	09/24/1976			Rabies	08/01/2016	No Doses Administered	08/25/2016	02/25/2019	Recommended based on Condition	Updated CVX code from 18 to 175/176, added description	4.0
2016-UC-0182																										2	08/08/2016	08/08/2016			Rabies	08/01/2016	All Valid: Forecast Test	08/25/2016	02/25/2019	Recommended based on Condition	Updated Past Due date, added description	4.0
2016-UC-0183																										3	08/22/2016	08/22/2016	08/28/2016		Rabies	08/08/2016	All Valid: Forecast Test	08/25/2016	02/25/2019	Recommended based on Condition	Updated Earliest and Recommended Date to reflect 2 years after the last dose date	4.0
2016-UC-0184																										4	08/22/2018	08/22/2018		The 2 year booster should only be given after a serum sample has been tested for rabies virus neutralizing antibody. The booster should be administered if the serum titer fails to maintain a value of at least complete neutralization of a 1:5 serum dilution by rapid fluorescent focus inhibition test.	Rabies	08/22/2016	All Valid: Forecast Test	08/25/2016	02/25/2019	Recommended based on Condition	Updated to reflect an additional contraindication or observation, added a description.	4.0
2016-UC-0185																										-					Rabies	07/29/2016	All Valid: Forecast Test	08/26/2016	02/25/2019	Not recommended: contraindication	Updated to reflect an additional contraindication or observation, added a description.	4.0
2016-UC-0186																										-					Rabies	01/13/2016	All Valid: Forecast Test	08/26/2016	02/25/2019	Not recommended: contraindication	Added descriptions	4.0
2016-UC-0187																										-				This vaccine should be given at least 2 weeks before potential exposure. Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week	Yellow Fever	03/13/2016	All Valid: Forecast Test	08/22/2016	02/25/2019	Recommended based on Condition	Updated to reflect an additional Condition/ observation and updated booster dose to be administered at 5 years later.	4.0
2016-UC-0188																										3	07/10/2026	07/10/2026			Typhoid	07/10/2021	All Valid: Forecast Test	08/29/2016	03/04/2019	Recommended based on Condition		4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2016-UC-0189																										-					Typhoid	08/15/2016	All Valid: Forecast Test	08/22/2016	03/04/2019	Recommended based on Condition	Updated to reflect an additional contraindication/observation.	4.0
2016-UC-0190																										1	07/22/2000	07/22/2000	07/21/2059		Pneumococcal	10/13/2016	No Doses Administered	08/22/2016	03/04/2019	Recommended based on Condition	Updated to reflect an additional Condition/observation. Also updated Past Due date.	4.0
2016-UC-0191																										2	07/22/2059	07/22/2059			Pneumococcal	10/13/2016	All Valid: Forecast Test	08/22/2016	03/04/2019	Recommended based on Condition	Updated to reflect an additional Condition/observation.	4.0
2016-UC-0192																										1	08/14/1971	08/14/1971	08/13/2030		Pneumococcal	07/12/2016	No Doses Administered	08/26/2016	03/04/2019	Recommended based on Condition	Updated to reflect correct Past Due date	4.0
2016-UC-0193																										2	08/14/2030	08/14/2030			Pneumococcal	07/12/2016	All Valid: Forecast Test	08/26/2016	03/04/2019	Recommended based on Condition	Added description	4.0
2016-UC-0194																										1	03/23/2007	03/23/2007			HepB	05/19/2016	No Doses Administered	08/30/2016	03/04/2019	Recommended based on Condition	Added description	4.0
2016-UC-0195																										2	06/16/2016	06/16/2016			HepB	05/19/2016	All Valid: Forecast Test	08/30/2016	03/04/2019	Recommended based on Condition	Updated Earliest and Recommended to represent a 4 month interval after the 1st dose	4.0
2016-UC-0196																										3	09/19/2016	09/19/2016			HepB	06/16/2016	All Valid: Forecast Test	08/30/2016	03/04/2019	Recommended based on Condition	Updated the third dose to reflect 4 mos from dose #1, added general description	4.0
2016-UC-0197																										-					HepB	09/19/2016	All Valid: Forecast Test	08/30/2016	03/14/2019	Recommended based on Condition	Updated to reflect an Earliest and Recommended data of 07/13/79.07/13/1979, added description	4.0
2016-UC-0198																										1	07/13/1979	07/13/1979			Meningococcal	08/02/2016	No Doses Administered	08/02/2016	03/14/2019	Recommended based on Condition	.	4.0
2016-UC-0200																										-					HepB	02/12/2016	All Valid: Forecast Test	08/26/2016	03/14/2019	Not recommended: contraindication	Updated to reflect an additional contraindication/observation/observation.	4.0
2016-UC-0201																										-					Rabies	04/27/2016	All Valid: Forecast Test	08/26/2016	03/14/2019	Not recommended: contraindication	added description	4.0
2016-UC-0202																										-				Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health care facility.	MMR	08/09/2016	No Doses Administered	08/09/2016	03/14/2019	Not recommended: contraindication		4.0
2016-UC-0203																										-					MenB	06/28/2016	All Valid: Forecast Test	09/19/2016	03/14/2019	Not recommended: contraindication	Updated to reflect an additional contraindication/observation. Added description	4.0
																									-					HPV	01/23/2016	All Valid: Forecast Test	01/09/2017	03/14/2019	Recommended based on Condition	Updated to reflect an additional Condition/observation.	4.0
2017-UC-0001																																						4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
																										1	10/01/2010	10/01/2012	10/28/2014		HPV		No Doses Administered	01/10/2017	12/02/2019	Recommended based on Condition	added a past due date. Updated to reflect an additional Condition/ observation. Added description	4.1
2017-UC-0002																									2	02/05/2017	02/05/2017	04/29/2017		HPV	01/03/2017 01/08/2017	All Valid: Forecast Test	02/02/2017	12/02/2019	Recommended based on Condition	Added past due date Added description	
2017-UC-0003																									3	06/08/2017	07/08/2017	09/04/2017		HPV		All Valid: Forecast Test	02/02/2017	03/18/2019	Recommended based on Condition	Added description	4.1
2017-UC-0004																									-					HPV	07/08/2017	All Valid: Forecast Test	02/02/2017	03/18/2019	Recommended based on Condition	Added description	4.0
2017-UC-0005																									1	06/02/2014	06/02/2016	06/29/2018		HPV	09/30/2017 08/01/2016	No Doses Administered	02/02/2017	12/02/2019	Recommended based on Condition	Added past due date Added description	4.0
2017-UC-0007																									2	08/29/2016	08/29/2016	11/20/2016		HPV	08/01/2016	All Valid: Forecast Test	02/02/2017	03/08/2019	Recommended based on Condition	Added description	4.1
2017-UC-0008																									3	01/01/2017	02/01/2017	03/28/2017		HPV	08/29/2016	All Valid: Forecast Test	02/02/2017	12/02/2019	Recommended based on Condition	Updated earliest, recommended, and past due dates Added description	4.0
2017-UC-0009																									-					HPV	01/23/2017	All Valid: Forecast Test	02/02/2017	03/26/2019	Recommended based on Condition	Added description	4.1
2017-UC-0010																									1	09/02/2005	09/02/2005			MenB		No Doses Administered	03/20/2017	03/26/2019	Recommended based on Condition	Added description	4.0
2017-UC-0011																									2	03/30/2017	03/30/2017			MenB	03/02/2017 03/02/2017	All Valid: Forecast Test	03/20/2017	12/02/2019	Recommended based on Condition	Updated recommended date from 03/30/2017 to 03/30/2017 Added description	4.0
2017-UC-0012																									3	07/13/2020	07/13/2020			Meningococcal		All Valid: Forecast Test	03/20/2017	03/26/2019	Recommended based on Condition	Added description	4.1
2017-UC-0014																									1	02/17/2000	02/17/2000			Cholera	07/13/2015	No Doses Administered	07/18/2017	03/26/2019	Recommended based on Condition	Added description	4.0
2017-UC-0015																															07/18/2017						4.0

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2017-UC-0016																									-					Cholera	07/18/2017	All Valid: Forecast Test	07/18/2017	03/26/2019	Recommended based on Condition	Added description	4.0
2017-UC-0017																									-					Cholera		No Doses Administered	08/22/2017	12/02/2019	Not recommended: contraindication	Added Observation Code 008, updated 080 to 119 Added description	4.1
2018-UC-0001																									-					MenB	08/01/2017 09/22/2018	All Valid: Forecast Test	10/19/2018	12/02/2019	Recommended based on Condition	Updated Vaccine Group type added description	4.1
2018-UC-0002																									3	01/02/2023	01/02/2023			Meningococcal	01/02/2018	All Valid: Forecast Test	10/29/2018	12/02/2019	Recommended based on Condition	Removed past due date added description	4.1
2018-UC-0004																									1	06/23/2016	06/23/2016			HepB		No Doses Administered	12/17/2018	03/28/2019	Recommended based on Condition	added description	4.1
2018-UC-0005																									2	07/25/2018	07/25/2018	08/21/2018		HepB	06/27/2018 06/27/2018	All Valid: Forecast Test	12/17/2018	03/28/2019	Recommended based on Condition	added description	4.0
2018-UC-0006																									-					HepB	07/25/2018	All Valid: Forecast Test	12/17/2018	03/28/2019	Recommended based on Condition	added description	4.0
2019-UC-0001																									-											Added booster dose information	4.0
2019-UC-0002																									1	04/29/2019	04/29/2019			Japanese Encephalitis Pneumococcal	07/19/2019	All Valid: Forecast Test No Doses Administered	03/01/2019	07/20/2019	Recommended based on Condition Recommended based on Condition		4.0
2019-UC-0003																									2	08/26/2019	08/26/2019			Pneumococcal	07/01/2019	All Valid: Forecast Test	07/10/2019	07/10/2019	Recommended based on Condition		4.0
2019-UC-0008																									1						07/01/2019		07/10/2019	07/10/2019		Updated test case observation code.	4.0
2019-UC-0009																									2	08/06/2019	08/06/2019	08/06/2019		Pneumococcal	08/06/2019	No Doses Administered	08/07/2019	12/02/2019	Recommended based on Condition	Updated test case scenario.	4.1
2019-UC-0010																									-	08/06/2020	08/06/2020	08/06/2020		Pneumococcal	08/06/2019	All Valid: Forecast Test	08/07/2019	12/06/2019	Recommended based on Condition	Updated test case scenario.	4.1
2019-UC-0011																									1						08/06/2020	All Valid: Forecast Test	08/07/2019	12/06/2019	Recommended based on Condition		4.1
2019-UC-0012																									2	08/15/1990	08/15/1990			HepB	09/06/2019	No Doses Administered	12/06/2019	12/06/2019	Recommended based on Condition		
2019-UC-0013																									3	10/04/2019	10/04/2019	11/01/2019		HepB	09/06/2019	All Valid: Forecast Test	12/06/2019	12/06/2019	Recommended based on Condition		
																										11/01/2019	11/01/2019			HepB	10/04/2019	All Valid: Forecast Test	12/06/2019	12/06/2019	Recommended based on Condition		

CDC_Test_ID	MVX_4	Evaluation_Status_4	Series_Type_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Series_Type_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Series_Type_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Series_Type_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Administrative_Guidance	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_added	Date_updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version
2019-UC-0014																										4	11/29/2019	11/29/2019			HepB	11/01/2019	All Valid: Forecast Test	12/06/2019	12/06/2019	Recommended based on Condition		
2019-UC-0015	DVX	Valid	risk																												HepB	11/29/2019	All Valid: Forecast Test	12/06/2019	12/06/2019	Recommended based on Condition		